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A B S T R A C T
Background
Increased intracranial pressure has been shown to be strongly associated with poor neurological outcomes and mortality for patients with
acute traumatic brain injury. Currently, most eLorts to treat these injuries focus on controlling the intracranial pressure. Hypertonic saline
is a hyperosmolar therapy that is used in traumatic brain injury to reduce intracranial pressure. The eLectiveness of hypertonic saline
compared with other intracranial pressure-lowering agents in the management of acute traumatic brain injury is still debated, both in the
short and the long term.
Objectives
To assess the comparative eLicacy and safety of hypertonic saline versus other intracranial pressure-lowering agents in the management
of acute traumatic brain injury.
Search methods
We searched Cochrane Injuries' Specialised Register, CENTRAL, PubMed, Embase Classic+Embase, ISI Web of Science: Science Citation
Index and Conference Proceedings Citation Index-Science, as well as trials registers, on 11 December 2019. We supplemented these
searches with searches of four major Chinese databases on 19 September 2018. We also checked bibliographies, and contacted trial authors
to identify additional trials.
Selection criteria
We sought to identify all randomised controlled trials (RCTs) of hypertonic saline versus other intracranial pressure-lowering agents for
people with acute traumatic brain injury of any severity. We excluded cross-over trials as incompatible with assessing long-term outcomes.
Data collection and analysis
Two review authors independently screened search results to identify potentially eligible trials and extracted data using a standard data
extraction form. Outcome measures included: mortality at end of follow-up (all-cause); death or disability (as measured by the Glasgow
Outcome Scale (GOS)); uncontrolled intracranial pressure (defined as failure to decrease the intracranial pressure to target and/or requiring
additional intervention); and adverse events e.g. rebound phenomena; pulmonary oedema; acute renal failure during treatment).
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Main results
Six trials, involving data from 287 people, met the inclusion criteria. The majority of participants (91%) had a diagnosis of severe traumatic
brain injury. We had concerns about particular domains of risk of bias in each trial, as physicians were not reliably blinded to allocation,
two trials contained participants with conditions other than traumatic brain injury and in one trial, we had concerns about missing
data for important outcomes. The original protocol was available for only one trial and other trials (where registered) were registered
retrospectively.
Meta-analysis for both the primary outcome (mortality at final follow-up) and for 'poor outcome' as per conventionally dichotomised GOS
criteria, was only possible for two trials. Synthesis of long-term outcomes was inhibited by the fact that two trials ceased data collection
within two hours of a single bolus dose of an intracranial pressure-lowering agent and one at discharge from the intensive care unit (ICU).
Only three trials collected data aPer participants were released from hospital, one of which did not report mortality and reported a 'poor
outcome' by GOS criteria in an unconventional way. Substantial missing data in a key trial meant that in meta-analysis we report 'best-
case' and 'worst-case' estimates alongside available case analysis. In no scenario did we discern a clear diLerence between treatments for
either mortality or poor neurological outcome.
Due to variation in modes of drug administration (including whether it followed or did not follow cerebrospinal fluid (CSF) drainage, as
well as diLerent follow-up times and ways of reporting changes in intracranial pressure, as well as no uniform definition of 'uncontrolled
intracranial pressure', we did not perform meta-analysis for this outcome and report results narratively, by individual trial. Trials tended
to report both treatments to be eLective in reducing elevated intracranial pressure but that hypertonic saline had increased benefits,
usually adding that pretreatment factors need to be considered (e.g. serum sodium and both system and brain haemodynamics). No trial
provided data for our other outcomes of interest. We consider evidence quality for all outcomes to be very low, as assessed by GRADE;
we downgraded all conclusions due to imprecision (small sample size), indirectness (due to choice of measurement and/or selection of
participants without traumatic brain injury), and in some cases, risk of bias and inconsistency.
Only one of the included trials reported data on adverse eLects; a rebound phenomenon, which was present only in the comparator group
(mannitol). None of the trials reported data on pulmonary oedema or acute renal failure during treatment. On the whole, trial authors do
not seem to have rigorously sought to collect data on adverse events.
Authors' conclusions
This review set out to find trials comparing hypertonic saline to a potential range of other intracranial pressure-lowering agents, but only
identified trials comparing it with mannitol or mannitol in combination with glycerol. Based on limited data, there is weak evidence to
suggest that hypertonic saline is no better than mannitol in eLicacy and safety in the long-term management of acute traumatic brain
injury. Future research should be comprised of large, multi-site trials, prospectively registered, reported in accordance with current best
practice. Trials should investigate issues such as the type of traumatic brain injury suLered by participants and concentration of infusion
and length of time over which the infusion is given.
P L A I N   L A N G U A G E   S U M M A R Y
Concentrated salt solution versus other treatments to lower pressure around the brain for people with acute traumatic brain injury
Review question
We reviewed the evidence for the eLectiveness and safety of infusions (where a substance is given through a vein) of hypertonic saline
(concentrated salt (sodium chloride) solution) compared with other types of infusion for lowering intracranial pressure (pressure in and
around the brain) in the management of acute traumatic brain injury.
Background
Acute traumatic brain injury (sudden and severe injury to the brain, oPen due to accidents) is a leading cause of death and disability
worldwide, especially in children and young people. Intracranial hypertension (the build-up of high pressure within and around the brain)
is common aPer damage to the brain. This is because the skull is a rigid compartment that contains three parts: soP brain tissue, blood, and
cerebrospinal fluid. If an increase occurs in the volume of one component, such as hematomas (collections of blood) within the brain's soP
tissue, the volume of one or more of the other components must decrease - otherwise intracranial pressure will rise. If intracranial pressure
increases beyond certain limits, there is an imbalance, and blood flow to the brain becomes dangerously low. This high intracranial pressure
can cause serious eLects that include brain damage and death. Hyperosmolar therapy is an important treatment for raised intracranial
pressure. One kind of hyperosmolar therapy involves an infusion of concentrated (hypertonic) saline (table salt/sodium chloride) solution
into the blood; other treatments including mannitol (a form of sugar) can also be used. Such treatments may lower intracranial pressure
by reducing water volume inside and between brain cells.
Trial characteristics
In December 2019, the authors of this review searched for randomised trials comparing the eLects and safety of hypertonic saline with
other fluid infusions that are used to lower intracranial pressure in people with acute traumatic brain injury. The review authors searched
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a wide variety of medical databases and identified six relevant trials, with data from a total of 287 participants. The trials were all
randomised controlled trials, which produce the most reliable evidence. Three trials took place in India, one each in France and Germany,
and one included people from both France and Israel. Most people in the trials (91%) had traumatic brain injury. Trials compared various
concentrations of hypertonic saline with either mannitol or mannitol in combination with glycerol.
Key results
Based on limited data of these six trials, there is no clear evidence to support the use of hypertonic saline infusion over mannitol infusion
for people with acute traumatic brain injury. Adverse eLects of the treatments were not routinely measured.
More research is needed. Future trials should be larger and better reported. Potential points for research include investigating whether
there is a particular concentration of infusion, or length of time over which the infusion is given, that benefits people with raised intracranial
pressure aPer traumatic brain injury.
Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury (Review)





































































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Hypertonic saline compared with other intracranial pressure-lowering agents for acute traumatic
brain injury
Hypertonic saline compared with other intracranial pressure-lowering agents for acute traumatic brain injury
Patient or population: people with acute traumatic brain injury
Settings: intensive care units
Intervention: hypertonic saline (between 3% and 7.5% solution) delivered by infusions
Comparison: all other intracranial pressure-lowering agents eligible (but mannitol infusions the sole comparator within the included trials)
Illustrative comparative risks* (95% CI)



















2 RCTs reported mortality in the short term, prior to discharge from hospital.
Meta-analysis was not possible.
1 RCT (n = 38) reported that 3/18 participants in the HTS group and 1/20 in the mannitol
group died in the first 6 days following treatment, after which no further deaths occurred
in the HTS group but a further 9 deaths occurred in the mannitol group prior to discharge.
At this time point, there is a slight trend favouring HTS compared to mannitol (RR 0.33, 95%
0.11 to 1.02).
The other RCT (n = 32, in which only a third of participants had TBI) reported that 7/17
(41.2%) participants in the HTS group and 9/15 (60%) in the mannitol group died by the end
of stay in the ICU. Here, HTS did not reduce all-cause mortality in people with acute TBI (RR
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data due to difference in






35.6% risk (worst case
for intervention, HTS)
30% risk (available case)
40% risk (worst case for intervention,
HTS)
30% risk (best case for intervention,
HTS)
RR 0.84 (0.46 to 1.55)
(available case)
RR 1.12 (0.66 to 1.89)






Pooling done with avail-
able, best-case and
worst-case scenarios. In
no case do results show
































































































































































44.4% risk (best case
for intervention, HTS)
RR 0.67 (0.38 to 1.18)









66.7% risk (worst case
for intervention, HTS)
75.6% risk (best case
for intervention, HTS)
72.5% risk (available case)
82.5% risk (worst case for intervention,
HTS)
72.5% risk (best case for intervention,
HTS)
RR 1.09 (0.82 to 1.44)
(available case)
RR 1.24 (0.97 to 1.58)
(worst case for inter-
vention, HTS)
RR 0.96 (0.74 to 1.24)






Pooling done with avail-
able, best-case and
worst-case scenarios
from two studies which
supplied sufficient data.




with any level of dis-
ability excluding persis-
tent vegetative state and






1 RCT reported a difference in the magnitude of ICP reduction and found both HTS and
mannitol effectively and equally reduced ICP levels with subsequent elevation of CPP and
CBF, although this effect was significantly stronger and of longer duration after HTS.
Another 2 RCTs reported a difference in the ratio of uncontrolled ICP between the 2 groups,
and the definition of uncontrolled ICP in these 2 RCTs differed, as did the time frames for
data collection. 1 of these RCTs found both interventions to be effective, but added pre-
treatment factors need to be considered (e.g. serum sodium and haemodynamics). The 5th
RCT found HTS to be more effective for increased ICP than mannitol but cautioned the ben-
efit in this trial might be explained by "local osmotic effects".
2 RCTs in which intervention was only given after CSF drainage had failed, reported the
mean fall in ICP following a dose averaged over hundreds of episodes across 4-6 days of
treatment. Of these 2 RCTs, 1 found HTS to be superior to mannitol; the other found no
clear difference between groups.
HTS vs mannitol vs mannitol plus glycerol
A 6th RCT comparing HTS with mannitol and also with mannitol plus glycerol reported
means and ranges of change within an hour following a single dose. They reported all 3 hy-
perosmolar agents (HTS, mannitol and mannitol plus glycerol) as effective, but HTS was
slightly superior, effecting a greater change in reducing ICP, and more quickly, than other





It is not possible to pool
these data because of
variations in timings and



































































































































































None of the RCTs reported on this outcome systematically, although it is mentioned in





This outcome was re-










No data available This outcome was not
reported.
*The basis for the assumed risk (e.g. the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; CPP: cerebral perfusion pressure; CSF: cerebrospinal fluid; HTS: hypertonic saline; ICP: Intracranial pressure: ICU: intensive care unit; RCT: ran-
domised controlled trial; RR: risk ratio; TBI: traumatic brain injury
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
aWe downgraded for imprecision (low number of participants), risk of bias and indirectness (1 trial included a mixed population of whom only a third had TBI).
bWe downgraded for imprecision, inconsistency and risk of bias.
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B A C K G R O U N D
Description of the condition
Traumatic brain injury is a major cause of death and disability
worldwide (Corrigan 2010). Intracranial hypertension secondary
to traumatic brain injury is well known to have a profound
influence on outcome, and severe intracranial hypertension has
been associated with higher morbidity (Miller 1977). Intracranial
pressure is the pressure in the cranium, and the brain has a
very limited ability to compensate for haemorrhage, swelling,
oedema, or mass eLects due to the invariant constraints of the
cranial vault (Stevens 2012). Intracranial pressure in the intact
cranium is determined by the brain parenchyma tissue pressure,
presence of mass lesions, cerebral blood volume, and intracranial
cerebrospinal fluid volume (Greve 2009). Intracranial hypertension
is defined as a sustained (longer than five minutes) elevation
of ICP above 20 mmHg (Bratton 2007). Sustained intracranial
hypertension indicates life-threatening neurological emergencies
that require immediate recognition and treatment to prevent
irreversible injury and death. In a review of trials of the value
of intracranial pressure in predicting outcomes in traumatic
brain injury, the risk of death was 18.4% for participants with
intracranial pressure less than 20 mmHg and 24.8% for participants
with intracranial pressure between 20 mmHg and 40 mmHg
but 55.6% for those with intracranial pressure greater than 40
mmHg (Treggiari 2007). Achieving a sustained reduction in elevated
intracranial pressure remains a focus of neurocritical care.
Description of the intervention
Currently available medical treatments for raised intracranial
pressure include hyperosmolar therapy, sedation and paralysis,
hyperventilation, barbiturates, hypothermia, steroids and surgical
intervention (Rangel-Castillo 2008).
Hyperosmolar therapy is the cornerstone of pharmaceutical
treatment for intracranial hypertension. The physiological basis
of osmotherapy was first published by Weed and Mckibben
(Weed 1919). Intravenous injection of a hypertonic solution was
followed by a marked decrease in size of the brain. Since that
time, mannitol, a sugar alcohol that acts as an osmotic diuretic,
causing sustained hyperosmolarity by dehydration, has become
the most widely used hyperosmolar solution to treat elevated
intracranial pressure. Increasingly, hypertonic saline has emerged
as an alternative hyperosmolar agent aPer several trials reported its
relative superiority, especially for refractory intracranial pressure
(Horn 1999; Khanna 2000; Oddo 2009).
Hypertonic saline firstly gained attention as a potentially more
eLective alternative to normal saline in the initial resuscitation of
haemorrhagic shock (Gunnar 1986). A survival benefit was shown
when used for patients with combined haemorrhagic shock with
head injury. The favourable eLect on survival was attributed to the
hyperosmolar characteristics of hypertonic saline and the resultant
reduction in intracranial pressure. Since then, more clinical trials
have found that the intravenous bolus administration of hypertonic
saline resulted in a sustained reduction of intracranial pressure
on patients with traumatic cerebral oedema, even when elevated
intracranial pressure is resistant to other intracranial pressure-
lowering agents including mannitol (Ziai 2007).
Although treatment protocols for administering hypertonic saline
vary (Mortazavi 2012), retrospective trials suggest a definite
intracranial pressure reduction is observed with the use of
hypertonic saline independent of the dosage, the concentration or
the administration strategy (Lewandowski-Belfer 2014; Maguigan
2017; Roquilly 2011). Reported concentration and volume of
hypertonic saline for clinical use range from 2% to 23.4% in
concentration and 10 to 30 mL/kg in volume (Mortazavi 2012).
How the intervention might work
The intracranial pressure-lowering mechanisms of hypertonic
saline solutions are believed to be due to their eLects on
microcirculation and osmotic action (Ziai 2007). Hypertonic
saline solutions decrease serum viscosity and hematocrit, leading
to an increase in cerebral perfusion and causing cerebral
arteriole vasoconstriction that reduces cerebral blood volume and
intracranial pressure. Water always flows from body compartments
with low osmolality to those with higher osmolality. Hypertonic
saline solutions increase plasma osmolality aPer administration,
thus promoting gradual movement of water from tissues into the
circulation. As fluid moves into the vascular space and is carried
away by the blood, the brain shrinks and intracranial pressure is
reduced.
Why it is important to do this review
Hyperosmolar therapy is standard practice in most neurosurgical
centres worldwide (Bratton 2007). The recent consensus suggest
the use of mannitol or hypertonic saline solutions for reducing
increased intracranial pressure in neuro-intensive care patients
(Oddo 2018). Guidelines for the management of severe pediatric
brain traumatic injury recommend bolus hypertonic saline (3%)
in patients with intracranial hypertension (Kochanek 2019).
Intravenous infusion of mannitol has been considered by some to
be the ‘gold standard’ for the treatment of increased intracranial
pressure, mostly due to its long history (Marko 2012). Some
clinical trials suggest that hypertonic saline solutions can reduce
raised intracranial pressure (Horn 1999; Kerwin 2009; Khanna 2000;
Worthley 1988), but its use can still be controversial in the field
of TBI. We undertook this review to enable better understanding
of the comparative eLicacy and safety of hypertonic saline versus
other intracranial pressure-lowering agents for people with acute
traumatic brain injury.
O B J E C T I V E S
To assess the comparative eLicacy and safety of hypertonic
saline versus other intracranial pressure-lowering agents in the
management of acute traumatic brain injury.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) with a parallel design. We
excluded cross-over trials as incompatible with assessing long-
term outcomes.
Types of participants
We included participants of any age, with clinically defined
traumatic brain injury of any severity, seen in the acute setting.
Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury (Review)
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Types of interventions
Any hypertonic saline in any dosage for any duration, given at any
time within eight weeks following injury. Hypertonic saline had to
be compared with another intracranial pressure-lowering agent,
such as mannitol, barbiturates or steroids.
We excluded any trials that used sodium lactate as an hypertonic
saline, as, although it is a hyperosmolar solution, its eLects
cannot be attributed to a classical osmotic eLect (Ichai 2009; Ichai
2013). Sodium lactate diLers fundamentally from sodium chloride
because lactate is a metabolisable anion; this means that even with
comparable osmolarity in vitro, sodium lactate becomes two times
less hypertonic than equiosmotic sodium chloride in the body.
Types of outcome measures
Primary outcomes
• Death at final follow-up (grouped by period of reporting e.g.
short term (while in ICU); long term (at six months)
Secondary outcomes
• 'Poor outcome' (death, persistent vegetative state or severe
disability) at final follow-up (as measured by the Glasgow
Outcome Scale (GOS); Jennett 1975; Teasdale 1974). The GOS
score, where possible, was converted into a dichotomous
outcome. A 'poor outcome' is defined above; a ‘good outcome’
includes GOS categories of moderate disability or good recovery.
• Uncontrolled intracranial pressure during treatment (we define
uncontrolled intracranial pressure as failure to decrease the
intracranial pressure to target and/or requiring additional
intervention; Burgess 2016).
• A 'rebound phenomenon' during treatment (we define rebound
phenomenon as intracranial pressure rising above its original
level aPer hyperosmolar therapy. Leakage of osmotic agent into
the brain parenchyma through an altered blood brain barrier
and secondary reversal of osmotic gradient with subsequent
increase in brain oedema is considered the major cause of
rebound).
• Pulmonary oedema during treatment.
• Acute renal failure during treatment.
Sample size calculation
At protocol stage, we judged that 474 people are required to have
a 90% chance of detecting, at a significance level of 5%, a decrease
in death from 27% in the control group to 15% in the experimental
group (Lu 2005).
Search methods for identification of studies
We did not restrict searches by date, language or publication status.
Electronic searches
The Cochrane Injuries' Information Specialist ran searches in
December 2019 (Appendix 1); we also report earlier searches
(Appendix 2). The main amendment in the updated search in
February 2017 was the inclusion of a more sensitive list of terms
for hypertonic saline solution and hyperosmolar therapy. Searches
were back-dated to accommodate these changes. Additional
searches were run in Chinese databases (see below) in August 2018.
No relevant records resulted from the latter searches, and these
were not re-run in 2019.
The Information Specialist ran searches on the following databases
(all years):
• Cochrane Injuries' specialised register (11 December 2019);
• Cochrane Central Register of Controlled Trials (CENTRAL; 2019,
Issue 12) in the Cochrane Library;
• Ovid MEDLINE databases (1946 to 11 December 2019);
• Embase Classic + Embase (OvidSP) (1947 to 11 December 2019);
• ISI Web of Science: Science Citation Index-Expanded (SCI-
EXPANDED) (1970 to 11 December 2019);
• ISI Web of Science: Conference Proceedings Citation Index-
Science (CPCI-S) (1990 to 11 December 2019).
Shuang Yang Liu, from the Department of Documentation and
Retrieval, Xiangya Medical College, Central South University,
searched the following Chinese databases in December 2013,
November 2017 and September 2018:
• ChinaBiologyMedicinedisc (CBMdisc);
• Wanfang Data;
• China National Knowledge Infrastructure (CNKI);
• VIP Database for Chinese Technical Periodicals.
The CBMdisc search strategy (Appendix 3) was adapted as
necessary for each of the other databases.
Searching other resources
We also searched the following clinical trials registers (December
2019):
• Clinicaltrials.gov (www.clinicaltrials.gov);
• World Health Organization (WHO) International Clinical Trials
Registry Platform (apps.who.int/trialsearch/).
We checked the reference lists of all identified relevant articles.
Data collection and analysis
Selection of studies
Two review authors (HC and ZS) independently screened the
search results and discussed the trials eligible for inclusion for
searches run in 2013, examining each potential title. If titles were
ambiguous, we read the abstracts. We resolved disagreement
about inclusion of one trial (Ichai 2009), by seeking the advice
of the trial's correspondence author by email (Ichai 2013), as the
trial author informed us that they had used sodium lactate to
decrease the raised intracranial pressure, and that sodium lactate
diLers fundamentally from sodium chloride because the absence
of significant modification of plasma osmolality does not support a
pure osmotic eLect of sodium lactate, we excluded this trial.
For the searches run aPer in 2017 and thereaPer, JD assisted HC in
screening the English language results.
Data extraction and management
Two review authors (HC and ZS; HC and JD) independently
extracted and recorded the data on specially designed forms and
subsequently cross-checked the data. We collected the following
data from the trial reports: trial design, participant characteristics,
intervention characteristics, outcome data, and adverse eLects.
Participant characteristics included age, sex and traumatic brain
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injury severity. Intervention characteristics included concentration,
dosage, timing of administration and duration of intervention.
Outcome measures included uncontrolled intracranial pressure
(however defined by trial authors: our own definition was "failure
to decrease the intracranial pressure to target and/or requiring
additional intervention", mortality and disability according to GOS
score (Jennett 1975; Teasdale 1974), dichotomised in the standard
way. We used Review Manager 2014 soPware in the completion of
this review.
Assessment of risk of bias in included studies
Two review authors (HC and JD) independently assessed the risk
of bias for each included trial. We evaluated six domains: sequence
generation, allocation concealment, blinding (subdivided into
blinding of participants, treating physicians, and outcome
assessors), incomplete outcome data, selective outcome reporting
and other sources of bias. We judged the risk of bias in each
category as high risk, low risk or unclear risk according to guidance
on use of the risk of bias tool within The Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2017). We approached
the contact authors of all included trials to ask for clarification of
trial methods and to request the trial protocols (where available).
We intended to resolve any disagreements by consensus; however,
no disagreements arose between review authors on the 'Risk of
bias' judgements.
Measures of treatment e?ect
For dichotomous data, we present results as summary risk ratios
(RRs) with 95% confidence intervals (CIs). Additionally, as described
above, we determined at the protocol development stage that
we would transform the GOS score into a dichotomous outcome.
'Death or disability' would mean death, persistent vegetative state
and severe disability; a 'good outcome' would include moderate
disability and good recovery.
Where trials presented other data as continuous data, such as
'uncontrolled intracranial pressure during treatment', we proposed
to use mean diLerences (MDs) or standardised mean diLerences
(SMDs), if data were measured in varying scales, with 95% CIs
between the trial groups.
Unit of analysis issues
We did not include cross-over RCTs in this review, although we
identified several. For rapidly changing intracranial pressure, we
determined at protocol stage that although feasible, cross-over
trials were not suitable for our review question, given that our
primary outcome (death) was a long-term one and that even in
the short term, 'carry-over' eLects confound the estimates of the
treatment eLects in rapidly changing intracranial pressure.
Our searches did not identify any cluster-randomised trials. For the
one trial included within this review with more than two eligible
arms, data were unsuitable for pooling with those from other trials.
Therefore, for this review, the unit of analysis is the individual
participant.
Dealing with missing data
As planned at protocol stage, we made every eLort to contact trial
authors to acquire missing data. We initially planned to prefer data
reported according to intention-to-treat principles. As this was not
possible in one key trial, we conducted best-case and worst-case
analyses for the primary outcome (death at longest follow-up) and
also for GOS (in trials that provided data suitable for this purpose).
Assessment of heterogeneity
We planned at protocol stage to use the Chi2 test and the I2 statistic
(Higgins 2003), to assess statistical heterogeneity and we report
these values, where relevant, in Results. Heterogeneity in terms of
treatment protocols, mode and timing of intervention delivery are
described below, and discussed in relevant sections of the review
(Deeks 2019).
Assessment of reporting biases
In the future, if meta-analysis is feasible and if more than 10 trials
are available for the primary outcome, we plan to use a funnel plot
to assess publication bias.
In this version of the review, we compared the trial protocols or trial
registrations (where available) with the published reports, to assess
the likelihood of selective outcome reporting.
Data synthesis
We planned, if data were available for the same outcome measure
in more than one trial, to attempt a meta-analysis, analysing
outcomes providing dichotomous data using the RR and 95%
CI using a fixed-eLect model, conducting all analyses using
Review Manager 5 (Review Manager 2014). We did not anticipate
continuous outcomes at protocol stage, but henceforth plan to do
so utilising MD where the same scales are used, and SMD where
diLerent trials report diLerent scales, with 95% CI.
Subgroup analysis and investigation of heterogeneity
We planned to explore the eLects by subsets of participants
(children and adults) and by subsets of interventions (e.g. diLerent
dosage and diLerent duration, with or without a colloid), but data
were not suLicient for such analyses for the present version of
the review. We will attempt these subgroup explorations in future
versions of the review if and when there are suLicient data.
Sensitivity analysis
We planned to perform a sensitivity analysis for allocation
concealment (adequate vs 'unclear' or 'not done'), but there were
not enough trials to enable us to do so.
R E S U L T S
Description of studies
See also: Characteristics of included studies; Characteristics of
excluded studies.
Results of the search
Initial searches run in December 2013 identified 2841 records. APer
deduplication, 2488 potentially relevant search results remained,
which we (HC and ZS) screened. We excluded 2478 of these records
on the basis of their title or abstract. We examined the full text of
the 10 remaining reports, and thus identified three trials that met
the inclusion criteria, and seven were formally excluded.
An update search (10 February 2017) retrieved 1249 new records,
of which 740 proved to be internal duplicates or overlaps with
previous searches, yielding 509 unique records. We identified and
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included one further eligible trial (Jagannatha 2016), and assessed
and excluded a further 11 reports. We ran 'top-up' searches in
August 2018 and in December 2019. The 2018 searches found 265
records, 204 records when deduplicated, which we screened. We
did not include any eligible trials, but nine were formally excluded
at full-text stage. The 2019 searches identified 217 records, 180
when deduplicated. Of these, we identified and included two
eligible trials (Kumar 2019; Patil 2019), and formally excluded two
trials. The trial identification process is outlined in Figure 1 (Moher
2009).
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Figure 1.   Study flow diagram
 
We have identified one large trial as ongoing. In March 2019, we
learned of a relevant RCT soon to commence in the UK, likely to
report aPer 2023 (Salt or Sugar 2019), details of which can be found
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in Characteristics of ongoing studies; a record of this was identified
in register searches later in the year.
Included studies
Design
All six included trials (Cottenceau 2011; Francony 2008;
Harutjunyan 2005; Jagannatha 2016; Kumar 2019; Patil 2019), were
conducted as parallel, RCTs. Five involved two arms and one (Patil
2019), three arms.
Sample sizes
Sample sizes tended to be small, ranging from 20 (Francony 2008),
to 120 (Patil 2019). Data from 287 participants overall are included
within this review, but as described below, 9% of these participants
did not have diagnoses of traumatic brain injury. At protocol stage,
we had estimated that 474 people were required to have a 90%
chance of detecting, as significant at the 5% level, a decrease in
death from 27% in the control group to 15% in the experimental
group (Lu 2005); this target was manifestly not met within this
review.
Only one trial - the smallest included within the review (Francony
2008, n = 20), which did not collect data beyond 120 minutes
of infusion, reported undertaking a power calculation, using the
following assumptions: "The study population size for the trial was
calculated assuming a 40% ± 15% ICP [intracranial pressure] in
the HSS group and a 20% ± 15% ICP reduction in the mannitol
group, according to previous studies ....Based on the formula for a
normal distribution and assuming a two-sided type I error of .05
and a power of .80, ten patients in each of the two groups were
required" (Francony 2008, p 796).
No other trial reported undertaking a sample size calculation a
priori, and all other trials (with the exception of Patil 2019), describe
their small sizes as limitations. The authors of Jagannatha 2016 (n
= 38), and Kumar 2019 (n = 30), both explicitly reported small trial
size underneath the 'limitations' sections of their papers; likewise,
investigators involved in Cottenceau 2011 (n =47), comment that
"although the number of included patients was significantly larger
than the number of patients included in most other comparable
studies, the figures remained smaller than what would be needed
to draw definite conclusions, especially when diLerences observed
between subgroups are analyzed" (Cottenceau 2011, p. 210).
Authors of Harutjunyan 2005 (n =32) also mention "the small
patient population of each group" as a limitation, especially in
the context of the "heterogeneity in the underlying neurological
illness" (p R530).
Setting
All trials took place in ICUs, usually based within university
hospitals. Three trials were conducted in India (Jagannatha 2016;
Kumar 2019; Patil 2019), one trial each in France (Francony 2008),
and Germany (Harutjunyan 2005), whilst the sixth trial included
participants from both France and Israel (Cottenceau 2011). Trials
were published between 2005 and 2019; the earliest recruitment
period appears to have commenced in 2002 (Francony 2008), and
the latest in 2015 (Patil 2019).
Participants
Inclusion and exclusion criteria varied amongst trials. Two were
restricted solely to participants with traumatic brain injury severe
enough to require intracranial pressure monitoring (Cottenceau
2011; Jagannatha 2016); a third (Francony 2008), required that
they were stable patients (with or without traumatic brain injury)
with sustained elevated intracranial pressure of 20 mm Hg
for 10 minutes, not related to procedural pain (resulting in a
participant group of whom 85% (17/20) had severe traumatic
brain injury and the remainder of whom had suLered strokes).
The fourth included trial required that participants have severe
brain damage (Glasgow Coma Scale (GCS) < 8) with cerebral
oedema, resulting in a participant group of whom only 31% (10)
had a diagnosis of traumatic brain injury (the remainder had
subarachnoid haemorrhage (9); brain infarctions (7); intracerebral
haemorrhage (4) or "other" (2) (Harutjunyan 2005)). The inclusion
criteria for Patil 2019 were that participants be screened by CT "to
eliminate the need for surgery, then included if they had a GCS
≤8, and had sustained elevated ICP of >20 mm Hg for more than
5 minutes". The sole paediatric trial (Kumar 2019), required that
participants have severe traumatic brain injury, defined as a score
of ≤8 on the Pediatric GCS, and present within 24 hours of trauma.
The one trial that focused on children under 16 years (Kumar 2019),
did not report an overall mean for age, but provided ranges of
ages. Participants were very young; 18 out of 30 were under five
years of age, and one child was 22 months old. Within the trials
largely focused on adults, minimum age criteria ranged from 15
(Jagannatha 2016), to 16 (Cottenceau 2011), to 18 years (Francony
2008; Harutjunyan 2005); the mean ages of included participants
varied from around 30 (Jagannatha 2016) to 47 years (Harutjunyan
2005). In the four trials that reported on gender, male participants
constituted the majority.
In terms of severity, participants ranged from means of GCS scores
on admission of 7 (SD 2) to 8 (SD 2) in the two groups within
the Francony 2008 trial (n = 20), to the most severely aLected
participants within the review, those within the Jagannatha 2016
trial (n = 38; median GCS scores = 4 in the hypertonic saline
group (range 4 to 5) and 5 in the mannitol group (range 4 to 6).
Authors of the two 'mixed' trials, which did not focus on traumatic
brain injury, did not report the source of traumatic brain injuries
(Francony 2008; Harutjunyan 2005); authors of the traumatic
brain injury-only trials (Jagannatha 2016; Cottenceau 2011; Kumar
2019; Patil 2019), did. Where reported, road traLic accidents
accounted for the majority of traumatic brain injuries, followed
by falls, assaults and 'other'. Three trials explicitly categorised the
nature of lesions, for example, extradural haematoma, subdural
haematoma, contusions, intraventricular haemorrhage, diLuse
axonal injury (Cottenceau 2011; Jagannatha 2016; Kumar 2019).
Interventions
Initiation of therapy; mode of intracranial pressure assessment
All six trials provided a detailed treatment protocol showing the
stages by which clinicians determined if hyperosmolar therapy was
indicated. In one trial (Cottenceau 2011), hyperosmolar therapy
was initiated when intracranial pressure elevation was above 15
mmHg. In Kumar 2019, the sole pediatric trial, trial authors aimed
at maintaining an intracranial pressure of below 15 mmHg in
children between 1 and 10 years of age and 18 mmHg in children
aged 11 to 16 years of age, and treatment was only administered
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if intracranial pressure remained persistently above the cut-
oL value for more than five minutes, in spite of cerebrospinal
fluid drainage. The four other included trials (Francony 2008;
Harutjunyan 2005; Jagannatha 2016; Patil 2019), initiated the
trial medications if intracranial pressure exceeded the 20 mmHg
threshold; Jagannatha 2016 stood out amongst the adult trials for
initiating treatment only aPer cerebrospinal fluid drainage.
It must be noted that methods of intracranial pressure assessment
diLered between trials. Two trials (Harutjunyan 2005; Francony
2008), used a standard intraparenchymal intracranial pressure
device (Codman Microsensor intracranial pressure Monitoring
System; Codman & ShurtleL Inc, Raynham, MA, USA); one used
a subdural bolt (Patil 2019), one trial did not state technology
used (Cottenceau 2011), two used an intraventricular device
alongside an extraventricular device allowing cerebrospinal fluid
drainage (Jagannatha 2016; Kumar 2019). In these latter trials, the
hyperosmolar treatment that is the subject of this review was only
initiated if cerebrospinal fluid drainage failed to control intracranial
pressure, compelling one set of trial authors to see hyperosmolar
treatment in this context as a 'second-tier' and not a first-line
therapy (Kumar 2019).
Concentrations, duration of therapy and comparators
Four trials compared equiosmolar doses of hypertonic saline
to mannitol; a fiPh, equiosmolar doses of hypertonic saline,
mannitol and mannitol in combination with glycerol, the sixth trial
featured hypertonic saline hydroxyethyl starch versus mannitol.
Concentrations and durations of infusions varied and are
presented, put in order of concentration of hypertonic saline, as
follows:
• one trial (n = 120) compared 3% hypertonic saline with
20% mannitol and with mannitol 10% plus 10% glycerol
combination; "infused via the central venous line at a defined
infusion rate, that is, 6 mL/minute or 120 drops/minute
(osmolarity of mannitol, mannitol plus glycerol combination,
and 3% HTS [hypertonic saline] are almost the same, ie, 1100
mOsm/L, 1049 mOsmo/L, and 1027 mOsm/L, respectively). The
infusion was stopped when ICP [intracranial pressure] was
reduced to <15 mm Hg, which was our treatment goal" (Patil
2019, e222). Assessment stopped aPer a single infusion;
• two trials (Jagannatha 2016 (n = 38); Kumar 2019 (n = 30))
compared administration of either 3% saline or 20% mannitol in
an equiosmolar dose infused as a bolus through a central venous
catheter over five minutes. Both mannitol and hypertonic saline
were administered as 2.5 mL/kg doses. Both trials dealt with
multiple episodes of raised intracranial pressure over four to
six days, following cerebrospinal fluid drainage as mentioned
above;
* Jagannatha 2016 administered a maximum of three doses of
the same drug if the first dose of the osmotic agent failed to
decrease the intracranial pressure to below 20 mmHg;
* Kumar 2019 administered a maximum of two doses if the
agent failed to decrease the intracranial pressure to one of
two targets based on the age of the child (15 mmHg or 18
mmHg);
• one trial (n = 32) compared 7.2% hypertonic saline hydroxyethyl
starch (200/0.5) 6% versus 15% mannitol, infused via the central
venous line using an automated infusion system at a defined
infusion rate (Harutjunyan 2005). The infusion was stopped
when intracranial pressure was reduced to less than 15 mmHg,
defined as the treatment goal. Multiple infusions were oPen
required; assessment stopped aPer discharge from ICU.
• one trial (n = 20) compared a single infusion of 100 mL of 7.45%
saline (osmolarity, 2548 mOsm/L; hypertonic saline group)
versus 231 mL of 20% mannitol (osmolarity, 1100 mOsm/L;
mannitol group) for 20 minutes of administration via the central
venous catheter (Francony 2008). Assessment was performed
during a study period of 120 minutes;
• one trial (n = 47) compared hypertonic saline 7.5% (2 mL/kg)
versus mannitol 20% (4 mL/kg) delivered intravenously for 20
minutes (Cottenceau 2011); and as long as intracranial pressure
remained elevated and monitored, all participants had a daily
evaluation during which a baseline assessment was followed
by two additional tests performed at 30 and 120 minutes aPer
administration of hypertonic saline or mannitol.
Outcomes
The length of follow-up (from one hour post infusion, to six months)
impacted on the range of outcomes chosen. Four of six trials
assessed mortality; one at end of stay in ICU, one at discharge from
hospital and two at six months. We cannot disaggregate mortality
data from the overall neurological outcome (GOS categories) in two
trials (Cottenceau 2011; Kumar 2019).
All trials measured intracranial pressure, although in diLerent ways
and by diLerent means.
Neurological outcome, even when assessed by a single instrument
(GOS) used within three of six trials, did not make comparison
straightforward. At six months, two trials reported GOS results
dichotomised in the traditional way, grouping death, persistent
vegetative state and severe disability together as a 'poor' outcome
(Cottenceau 2011; Jagannatha 2016), a third trial dichotomised a
poor outcome as death or persistent vegetative state, versus all
other outcomes (Kumar 2019). Patil 2019 was short term in nature
and so measured only the GCS at baseline and one hour aPer a
successful infusion.
No trial appeared systematically to assess adverse eLects.
Each trial is described in more detail in the Characteristics of
included studies table and a separate table listing data reported by
each trial at baseline and within the trial is also supplied (Table 1).
Excluded studies
See also the Characteristics of excluded studies table.
29 trials are formally excluded from this review.
Studies excluded for design features
We excluded 16 trials in total due to features of their design. We
excluded five trials due to their cross-over design (Battison 2005;
Bourdeaux 2011; Huang 2014; Polushin 2009; Sakellaridis 2011).
Searches of the Chinese literature identified 11 trials, which had
to be excluded due to unreliable data or methods (incorrect 'T'
values, questionable sequence generation), which we could not
clarify through contact with trial authors (Huang 2015; Jin 2018; Li
2018; Liang 2013; Liu 2018; Mei 2016; Ni 2018; Shu 2015; Zhang 2014;
Zhang 2015; Zhang 2018).
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Termination
We excluded four registered trials because they were terminated,
largely due to diLiculties in recruitment (NCT01028339;
NCT01108744; NCT01111682; NCT01215019.
Miscellaneous (chiefly ineligible intervention or comparator)
We excluded nine trials for other reasons. We excluded two
trials (Jiang 2018; Yang 2019), because they compared diLering
doses of hypertonic saline, with no eligible control; one trial
(Jafari 2018), because they administered hypertonic saline to
both groups, with furesimide as an added treatment; and one
trial (Du 2017) because there was no defined trigger for starting
hyperosmotherapy to reduce ICP, and in addition, mannitol was
administrated Q8h (every 8 hours). Following email communication
with the trial author (Ichai 2013), we excluded Ichai 2009 because
they used sodium lactate with the aim of decreasing the raised
intracranial pressure; although sodium lactate is a hyperosmolar
solution, its eLects cannot be attributed to a classical osmotic
eLect. It diLers fundamentally from sodium chloride because
lactate is a metabolisable anion; this means that even with
comparable osmolarity in vitro, sodium lactate becomes two
times less hypertonic than equiosmotic sodium chloride in the
body. We excluded one trial (Hong 2017), because of ineligible
population. They administered hypertonic saline but not as a result
of intracranial pressure monitoring. One trial appeared to meet
the inclusion criteria, but was a nontherapeutic investigation that
only considered coagulation (Wang 2017). We excluded one trial
(Upadhyay 2010), for multiple reasons: quasi-randomisation; too
low a proportion of participants with traumatic brain injury (only
7% traumatic brain injury). We excluded one ongoing trial (Roquilly
2017), because its comparator, 'standard care', is unlikely to include
alternative intracranial pressure-lowering agents.
One trial (Vialet 2003). awaits classification (see also Characteristics
of studies awaiting classification) due to unreconciled
discrepancies in numbers of participants reported within the paper.
Risk of bias in included studies
Two figures show our assessment of the risk of bias of the included
trials (Figure 2; Figure 3).
 
Figure 2.   'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages
across all included trials. Six trials are included in this review
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All included trials reported acceptable methods of generating
randomisation sequence (either computer-generated random-
number tables, or sealed, opaque envelopes) and so we judged
them to be at low risk of bias.
Allocation concealment
Three trials (Cottenceau 2011; Francony 2008; Patil 2019),
concealed allocation by using sealed and opaque envelopes and we
judged them to be at low risk of bias. Harutjunyan 2005 and Kumar
2019 did not describe the method of allocation concealment,
and the assessment for both is thus 'unclear'. The trial author of
Jagannatha 2016 told us in a personal communication that, "we did




We judged all the trials to have a low overall risk of bias for blinding
of participants; all of the people recruited to the trials had a brain
injury severe enough to have a GCS score of 8 or lower, were
sedated, and so were unaware of the treatment they were receiving.
Treating physicians
Overall, we judged the included trials to have a high risk of bias
for blinding treating physicians. In Francony 2008, it was not
possible to blind administration because the two treatments were
of diLerent volumes. Cottenceau 2011 explained in 2015 through
correspondence that the team was well aware of the regimen at the
acute phase. Harutjunyan 2005, Jagannatha 2016, Kumar 2019 and
Patil 2019 did not describe blinding and it is unlikely to have been
ensured.
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Outcome assessors
We judged trials to have varying risk of bias in blinding outcome
assessors. Cottenceau 2011 told us in a personal communication
that, "as for the outcome, it was assessed in both centers by blinded
medical staL during follow-up visits or by phone calls issued
by blinded personnel". Kumar 2019 reported using an assessor
unaware of treatment status. In Francony 2008, Harutjunyan 2005
and Jagannatha 2016, objective outcomes such as laboratory
measures or death are unlikely to have been aLected by problems
of blinding. We judged the above trials at low risk of bias for blinding
outcome assessors. We judged risk of bias for blinding outcome
assessors in Patil 2019 as high risk, as they do not mention blinding
and all outcomes were assessed in the short-term.
Incomplete outcome data
Complete outcome data were available for Francony 2008 (n = 20)
and for Patil 2019 (n = 30), two trials that followed participants
up for a maximum of two hours post treatment. We therefore
assessed these trials as being at low risk of bias for this domain.
In Harutjunyan 2005, data from eight out of 40 (20%) of the
participants initially recruited were missing, but these participants
were withdrawn from analysis before initiation of treatment, as
their intracranial pressure never exceeded the treatment threshold
of 20 mmHg. Cottenceau 2011 excluded nine out of 56 randomised
participants early, either because of intracranial pressure lower
than 15 mmHg (n = 7) or serum osmolarity greater than 320
mOsm/L on admission (n = 2). Data for the remaining participants
were complete. As we consider the data of participants who never
reached treatment threshold to be missing completely at random,
we also judged these trials to be at low risk of bias. The paediatric
trial Kumar 2019 reported that they assessed data on an intention-
to-treat basis and these appear to be complete (all 30 participants
analysed at all time points), so we judged this trial to be at low risk
of bias for this domain.
In the sixth included trial (Jagannatha 2016), no data were missing
at the point where 22 surviving participants were discharged from
hospital, but we were confronted with the problem of missing data
for four participants in each group at the time of six-month follow-
up. Personal communication with trial authors confirmed that
contact could not be maintained with participants or their carers by
telephone (Jagannatha 2017). Data were insuLicient to impute and
we confined ourselves to using available data, conducting a best-
case and worst-case scenario analysis, and commenting on the
high risk of bias introduced by 35% loss to follow-up for surviving
participants leaving hospital. Given that this aLects our assessment
of the primary outcome for a large proportion of the sample of this
trial, we therefore assess the risk of bias for this domain to be 'high'.
Selective reporting
In correspondence with the trial authors during 2014, Francony
2008 sent us a trial protocol (Payen 2002): a comparison with
the completed trial revealed no suggestion of reporting bias; our
assessment for bias is therefore 'low'. The assessment for all other
trials is 'unclear' as either we could not identify any registration or
protocol (Cottenceau 2011; Patil 2019), or trials were retrospectively
registered (Harutjunyan 2005; Jagannatha 2016; Kumar 2019).
Other potential sources of bias
• Two of the trials included within this review did not
restrict recruitment to participants with traumatic brain injury
(Francony 2008; Harutjunyan 2005), meaning that only 91% of
included data come from participants meeting all our inclusion
criteria.
• In addition, as mentioned, trials within this review are small,
which means that it is not surprising that half report important
diLerences between groups at baseline.
* Authors of the second largest trial (Cottenceau 2011, n
= 47), note that, "Although there was a statistical trend
suggestive of a better outcome in patients in the MTL
[mannitol] group, similar diLerences found in the cerebral
metabolic rate of oxygen (CMRO2) values and GCS scores
on admission between the two groups probably indicated
some asymmetry in the degree of severity of injury and
accounted for this neurological outcome diLerence (Fig. 5; x2
p = 0.0662)" (Cottenceau 2011, p 2007).
* Potential bias may have run in the other direction in a second
trial, as trial authors noted here: "The occurrence of twice
the number of subdural hematomas in the mannitol group
(15 versus seven) may have introduced a bias. Subdural
hematomas by virtue of being a pathologically more severe
form of injury may have necessitated a higher number of
hyperosmolar boluses in the mannitol group" (Jagannatha
2016, p 73).
* Authors of a third trial report "the clinical values
in both groups were not normally distributed [at
baseline]" (Harutjunyan 2005, p R532).
* Authors of Jagannatha 2016 also note that some "[other]
methodological issues need to be taken into account when
interpreting our results. ... Though we intended to recruit
consecutive patients, some patients were excluded for
logistic reasons. The GCS at inclusion of the patient into
the trial was much lower in this trial compared with other
trials, with a median of 5 and 4 (eye opening and motor
scores) in the mannitol and HTS groups, indicating a more
severe injury. Some of the patients in the trial underwent
surgery, which might have conferred some benefit in terms
of ICP [intracranial pressure] reduction. The patients were
controlled for GCS at the time of inclusion and not the
type of lesion on CT scan. .... The groups, however, were
comparable with respect to the overall radiological profile
and findings at surgery. Also, to our surprise, even in the
operated patients, the initial reduction of ICP was followed
by a progressive increase over time. Poor glycaemic control in
the mannitol group may also have influenced the outcome in
these patients. The number of patients in the trial was small
and this limited our outcome analysis" (Jagannatha 2016) p
73.
• Authors of Kumar 2019 wrote that hyperosmolar therapy was
eLectively "used as a second tier treatment" - only aPer failure
of an extraventricular drain in promoting cerebrospinal fluid
drainage to reduce intracranial pressure. They wrote that,
"EVD [extraventricular drain] as an initial treatment may dilute
the eLect of hyperosmolar therapy. It is not known, whether
there will be any diLerence in intracranial pressure reduction
between mannitol and hypertonic saline if any of these agents
are administered as first-line therapy. Many centers do not
use EVD for ICP [intracranial pressure] monitoring. When ICP
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monitoring is done using parenchymal sensor, option of CSF
[cerebrospinal fluid] drainage is not available, and true eLect
of hyperosmolar therapy can be assessed". Related to this,
diLerent trials measured intracranial pressure in diLerent ways:
Patil 2019 listed the use of a subdural bolt, and they cited
their failure to assess the advantages or disadvantages of the
intracranial pressure-measuring technique as a limitation.
E?ects of interventions
See: Summary of findings for the main comparison Hypertonic
saline compared with other intracranial pressure-lowering agents
for acute traumatic brain injury
All included trials compared hypertonic saline with mannitol,




Three out of six included trials reported on our primary outcome
(mortality); timings varied and meta-analysis was feasible between
only two trials.
Mortality (short-term) prior to discharge from hospital
Jagannatha 2016 (n = 38) reported that there were four deaths
within the first six days of treatment, but did not specify in
which group the deaths occurred. Personal contact established that
during this period, three out of 18 participants in the hypertonic
saline group and one out of 20 in the mannitol group died. The
same trial further reported data on deaths aPer six days, but
before participants leP hospital, recording no further deaths in the
hypertonic saline group but a further nine in the mannitol group. At
this time point, there is a slight trend favouring hypertonic saline
compared to mannitol (RR 3.33, 95% CI 0.38 to 29.25).
Investigators within Harutjunyan 2005 (n = 32), reported that seven
of 17 (41.2%) people in the hypertonic saline group and nine of 15
(60%) people in the mannitol group died by the end of stay in the
ICU. Within this small trial with a mixed population of whom only
a third had traumatic brain injury, hypertonic saline did not reduce
all-cause mortality (RR 0.69, 95% CI 0.34 to 1.39).
Mortality at six months
We pooled data from two trials (Cottenceau 2011; Jagannatha
2016), for this outcome, but given the high loss to follow-up
in Jagannatha 2016 (8 of 22 participants who survived to leave
hospital could not be contacted at six months), we have chosen
to present the data three ways (per protocol, 'worst-case' scenario
for hypertonic saline and 'best-case' scenario for hypertonic saline;
Figure 4). Here we have considered the eLects of all four missing
participants from either group alternately surviving or dying.
Available data results are as follows. Per protocol RR 0.84 (95%
CI 0.46 to 1.55; I2 = 0%; 2 trials, 85 participants). 'Worst-case'
and 'best-case' scenarios suggest the following (extreme) potential
parameters of eLect: worst-case RR 1.12 (95% CI 0.66 to 1.89; I2 =
0%; 2 trials, 85 participants); best-case RR 0.67 (95% CI 0.38 to 1.18;
I2 = 50%; 2 trials, 85 participants). None of these analyses show a
diLerence between treatments.
 
Figure 4.   Forest plot of comparison 1. Hypertonic saline vs mannitol, outcome: 1.2 mortality: 6 months
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Secondary outcome
Poor outcome (measured by the dichotomised Glasgow Outcome
Scale)
At protocol stage, we planned to report this outcome in the
conventional manner, that is, by converting GOS scores into a
dichotomous outcome where ‘death or disability’ signifies death,
persistent vegetative state and severe disability; and a ‘good
outcome’ includes moderate disability and good recovery. Two
trials reported data suitable for pooling for this outcome at
six months (Cottenceau 2011; Jagannatha 2016), although the
uncertainty due to missing data from Jagannatha 2016 referred to
above remains a concern. We thus reported findings in a similar way
(available data, 'best-case' and 'worst-case').
Within Cottenceau 2011: 17 of 22 (77.3%) people in the hypertonic
saline group and 14 of 25 (56%) people in the mannitol group
died or had a severe disability at the end of the follow-up period.
In Jagannatha 2016, trial authors report that, "GOS scores at 6
months, dichotomized as unfavourable (GOS 1–3) and favorable
(GOS 4–5)" are regarded as "comparable (p = 0.21)" (Jagannatha
2016, p. 71). Twelve of 18 (67%) people in the hypertonic saline
group and 16 of 20 (80%) people in the mannitol group died or
had a severe disability at six months. These findings are diLicult to
interpret in the light of the missing data on mortality referred to
above. Pooling produces a result in which we have low confidence
due to missing data as well as acknowledged baseline imbalance in
Cottenceau 2011 (RR 1.09, 95% CI 0.82 to 1.44; I2 = 67%; 2 trials, 85
participants; Analysis 1.3). We have also presented best- and worst-
case scenarios in Figure 5.
 
Figure 5.   Forest plot of comparison: 1 Hypertonic saline versus mannitol, outcome: 1.3 GOS: poor outcome at 6
months (conventional dichotomisation).
 
Kumar 2019 included solely children aged under 16 years. They also
reported GOS, but dichotomised diLerently, grouping all children
who survived (regardless of severity of disability) against those who
died or remained in a persistent vegetative state. We could not,
therefore, pool findings with those above. Results suggest no clear
diLerence between groups (RR 0.72, 95% CI 0.14 to 3.61; 1 trial, 25
participants; Analysis 1.4).
Uncontrolled intracranial pressure
Only two trials (Francony 2008; Harutjunyan 2005) reported
‘uncontrolled ICP’ and they each had a diLerent definition of
‘uncontrolled ICP’. In addition, the unit of analysis of Harutjunyan
2005 is 'episodes', while Francony 2008 is 'participants', so we could
not incorporate them in a meta-analysis.
All six trials reported the eLect of HTS or mannitol on ICP. Three
trials (Francony 2008; Jagannatha 2016; Kumar 2019) reported
the mean magnitude of ICP reduction, with standard deviations.
The other three trials (Cottenceau 2011; Harutjunyan 2005; Patil
2019) reported the initial ICP prior to, and immediately following,
the administration by infusion of the study medication , in
the form of means and ranges. We could not pool data for
this outcome due to manifest heterogeneity in timings and
modes of assessment, and other issues (including non-normally
distributed data, diLering populations (adults and children, non-
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TBI participants)). Therefore, we report results for this outcome
narratively.
Cottenceau 2011: absolute ICP measurement values were reported
as 12.2 ± 6.1 mmHg and 13.9 ± 7.8 mmHg in the hypertonic
saline group versus 10.5 ± 6.8 mmHg and 13.6 ± 7.5 mmHg in
the mannitol group aPer 30 minutes and 120 minutes of the
infusion, respectively. The mean magnitude of intracranial pressure
reduction aPer 30 minutes and 120 minutes of the infusion in the
hypertonic saline groups were 1.70 mmHg higher (1.99 lower to
5.39 higher) and 0.30 mmHg higher (4.09 lower to 4.69 higher),
respectively. Trial authors reported that, "both HTS [hypertonic
saline] and MTL [mannitol] eLectively and equally reduced ICP
[intracranial pressure] levels with subsequent elevation of CPP
[cerebral perfusion pressure] and CBF [cerebral blood flow],
although this eLect was significantly stronger and of longer
duration aPer HTS ... Further, eLect of HTS on ICP appeared to be
more robust in patients with diLuse brain injury" (Cottenceau 2011,
p 2003).
Francony 2008: intracranial pressure was reported as being reduced
by 45% ± 19% of baseline values (-14 ± 8 mmHg) and by 32% ±
12% of baseline values (-10 ± 4 mmHg ) in the mannitol group
versus 35% ± 14% (-10 ± 5 mmHg) and by 23% ±10% (-6 ± 3
mmHg) in the HTS group at 60 minutes and at 120 minutes aPer
the start of the study medication infusion, respectively). Only one
person from the hypertonic saline group was a low responder to
osmotherapy (with a reduction in intracranial pressure of < 20%
of baseline values at 60 minutes aPer the start of infusion). Trial
authors found both interventions to be eLective for this outcome
but added pretreatment factors need to be considered (e.g. serum
sodium and haemodynamics).
Harutjunyan 2005: a total of 53 episodes of raised intracranial
pressure exceeding 20 mmHg from 15 people in the mannitol
group required infusion of trial medication. For four of these
episodes (7.5%), intracranial pressure was uncontrolled within an
average of 8.7 (4.2 to 19.9) minutes. 57 episodes of increased
intracranial pressure occurred in the 17 people in the hypertonic
saline group. For two of these episodes (3.5%), intracranial pressure
was uncontrolled within 6.0 (1.2 to 15.0) minutes. Trial authors
in this trial concluded hypertonic saline to be more eLective for
increased intracranial pressure than mannitol but cautioned that
the benefit in this trial might be explained by "local osmotic eLects"
as there had been no diLerences in baseline haemodynamics.
Jagannatha 2016: trial authors here report that mean fall in
intracranial pressure following a dose of hyperosmolar agent was
8.9 ± 8.4 mmHg in the mannitol group and 10.1 ± 8.7 mmHg in the
hypertonic saline group, based on a comparison of 488 episodes
of raised intracranial pressure across six days. The mean fall in
intracranial pressure following a dose of hyperosmolar agent in the
hypertonic saline group was 1.20 mmHg higher (-0.37 lower to 2.77
higher) than with mannitol. Trial authors reported that this was
significant and also that the percentage time for which intracranial
pressure remained below a threshold of 20 mmHg on day 6 was
significantly higher for hypertonic saline than mannitol. They also
reported that cerebrospinal fluid drainage was performed on 41 ±
38 occasions in the mannitol group and 45 ± 31 occasions in the HTS
group (p= 0.73).
Kumar 2019: trial authors report that most episodes of raised
intracranial pressure were first managed by cerebrospinal fluid
drainage which was eLective in "almost more than two thirds of
episodes". ThereaPer, if not managed and requiring administration
of a hyperosmolar agent, the mean (SD) reduction in intracranial
pressure was −5.67 (SD 3.9) in the hypertonic saline group; − 7.13
(SD 2.9) in the mannitol group (Kumar 2019, p 1003). Trial authors
report that the diLerence was not statistically diLerent.
Patil 2019: all findings in this trial relate to a single episode of
raised intracranial pressure, aPer which assessment was carried
on for a maximum of one hour (assessments were made at
10, 30 and 60 minutes). Investigators reported data in the
form of means and ranges (rather than standard deviations);
they then report findings in percentage improvements. All three
hyperosmolar agents (hypertonic saline, mannitol and mannitol
plus glycerol) were reported as eLective, but hypertonic saline was
slightly superior, eLecting a greater change in reducing intracranial
pressure, and more quickly, than other agents, while at a lower
dose. The "maximum change in ICP [intracranial pressure] occurred
aPer the bolus dose of 3% HTS [hypertonic saline]"; the "maximum
decrease in ICP was produced by 3% HTS (60%), followed by the
10% mannitol plus 10% glycerol combination group (57%) and then
20% mannitol (55%). When the 3 groups were compared, 3% HTS
required the lowest dose, that is, 1.4 mL/kg, followed by the 10%
mannitol plus 10% glycerol combination group, that is, 1.7 mL/
kg, and then the 20% mannitol group, that is, 2 mL/kg." The time
required to reduce intracranial pressure below 15 mm Hg was 16
minutes (range 6 to 39 minutes) in the 3% hypertonic saline group,
23 minutes in the mannitol group (range, 10 to 70 minutes) and 19
minutes in the 10% mannitol plus 10% glycerol combination group
(range, 7 to 50) minutes.
A rebound phenomenon during treatment
None of the trials reported on this outcome systematically,
although it is mentioned in passing as potentially aLecting those
treated with mannitol in one trial (Jagannatha 2016).
Pulmonary oedema during treatment
None of the trials reported data on pulmonary oedema during
treatment.
Acute renal failure during treatment
None of the trials reported data on acute renal failure during
treatment.
D I S C U S S I O N
Summary of main results
There are six trials, involving a total of 287 people, included in this
review. We assessed the overall risk of bias in most trials as unclear
or high, due either to mixed population or other factors, such as the
impact of incomplete outcome data.
Some pooling of data was possible for the primary outcome
(mortality), as well as for the outcome of 'poor outcome' as
assessed by traditional dichotomisation of GOS. We report other
results narratively. Our certainty in all results is very low. Not
enough people have been randomised into eligible trials to be able
to give a reliable result.
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Mortality
Two trials reported mortality in the short term, prior to discharge
from hospital. One (n = 38) reported that three out of 18 participants
in the hypertonic saline group and one out of 20 participants in
the mannitol group died in the first six days following treatment,
aPer which no further deaths occurred in the hypertonic saline
group but a further nine deaths occurred in the comparator group
(mannitol) prior to discharge (Jagannatha 2016). At this time point,
there is no clear diLerence between groups (RR 0.33, 95% CI, 0.11 to
1.02). In another trial (n = 32), in which only a third of participants
had traumatic brain injury), trial authors reported that seven of 17
(41.2%) people in the hypertonic saline group and 9 of 15 (60%)
people in the mannitol group died by the end of stay in the ICU
(Harutjunyan 2005). Here, hypertonic saline did not reduce all-
cause mortality in people with acute traumatic brain injury (RR 0.69;
95% CI 0.34 to 1.39). We were able to pool data for two trials (n =
85) for mortality, but given the high loss to follow-up in one, we
presented data in three ways (per protocol, 'worst-case' scenario
for hypertonic saline and 'best-case' scenario for hypertonic saline
and there was no diLerence between groups at any time point
(Cottenceau 2011;Jagannatha 2016).
'Poor outcome' on the GOS
Using the method described above for mortality at six-month
follow-up, and for the same reason, we present inconclusive results
for this outcome based on pooling of two trials (n = 85). Again, there
were no diLerences between groups; nor was there a diLerence in
GOS reported in a smaller trial (n = 30) in which the GOS scale was
dichotimised by grouping death and persistent vegetative status
versus all other outcomes.
Uncontrolled intracranial pressure
For the outcome of 'uncontrolled intracranial pressure', no meta-
analysis was feasible due to no uniform definition of 'uncontrolled
intracranial pressure', and heterogeneity in reporting intracranial
pressure changes. Therefore we reported these and all other results
by individual trial. Essentially, trial results indicated that both
treatments appeared eLective compared with baseline, with some
additional benefits for hypertonic saline, but the data are too few to
be definitive and treatment selection might be individually based
on sodium level and cerebral haemodynamics.
Adverse e?ects
None of the trials systematically reported data on adverse eLects,
such as a rebound phenomenon, pulmonary oedema or acute renal
failure during treatment.
Overall completeness and applicability of evidence
This review set out to compare hypertonic saline against a potential
range of other therapies. However, the only trials that met the
inclusion criteria involved mannitol or mannitol with glycerol as a
comparator. We thus have no evidence of how hypertonic saline
compares to other intracranial pressure-lowering agents.
In addition, despite having found six trials, all were of small sample
size and were powered (if powered at all) for short-term outcomes.
Heterogeneneity of modes of administration, dosages, outcome
measurement and populations were so diverse as to make meta-
analysis diLicult. Not all trials contained only participants with
traumatic brain injury, and those from 'mixed' trials reported little
about the source of participants' traumatic brain injury. Longer-
term (six-month) follow-up data were available from only three of
the six trials. Clinical evidence is therefore insuLicient at present to
answer the objectives of the review.
Quality of the evidence
As stated above, sample sizes were small (287 people across
six trials) and the outcome measures and methods used were
heterogeneous. Data were missing for our primary outcome
(mortality) as well as for 'poor outcome' on the GOS scale. Blinding
of this intervention is oPen unfeasible, an inevitable weakness in
such trials. A comment must also be made on the quality of the
reporting of trials included within this review. None were reported
in accordance with CONSORT standards (Moher 2010). Registration
of trials (where extant) was retrospective; only one protocol was
available. Results were equivocal and the quality of the evidence
was low to very low, as these issues obliged us to downgrade for a
variety of criteria.
Potential biases in the review process
The review is based on a thorough search of medical literature in
English and Chinese, and we believe it is a complete compilation of
the RCTs on this topic; however, we have made choices diLerently
to that of other systematic review authors in the area. We have not
incorporated data from one trial (Vialet 2003), used within other
reviews focusing on mannitol (Wakai 2013; Wang 2015), because of
unreconciled discrepancies within the paper. We have (unlike the
authors of Boone 2015, Burgess 2016 and Li 2015), excluded cross-
over trials. We maintain this is appropriate for our review question
and focus on long-term outcome.
Agreements and disagreements with other studies or
reviews
There are two literature reviews (Kamel 2011; Mortazavi 2012), of
hypertonic saline for treating raised intracranial pressure, which
included people with raised intracranial pressure from multiple
aetiologies, which found that hypertonic saline was more eLective
than mannitol.
One recent systematic review with meta-analysis (Rickard 2014),
found that both hypertonic saline and mannitol eLectively lower
intracranial pressure. Authors identified a trend favouring the use
of hypertonic saline solutions in people with acute traumatic
brain injury. However, this meta-analysis included three trials that
our review does not: two had cross-over designs (Battison 2005;
Sakellaridis 2011). We maintain that the issue of 'carry-over' eLects
in cross-over trials confounds the estimates of the treatment eLects
and further, that it is impossible to assess the eLect of hypertonic
saline on death and neurological outcomes aPer traumatic brain
injury in a cross-over trial. This review also incorporated data from
Ichai 2009, which we have excluded.
Another recent meta-analysis (Burgess 2016), found no clinically
important diLerences in mortality, neurological outcomes, and
intracranial pressure reduction between hypertonic saline or
mannitol in the management of severe traumatic brain injury. It
included data from four trials that we have excluded (Battison 2005;
Ichai 2009; Sakellaridis 2011; Vialet 2003), but fundamentally, our
conclusions are similar. Authors of Schwimmbeck 2019 performed
a systematic review, meta-analysis and trial sequential analysis
comparing hypertonic saline and mannitol, concluding that there
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were, "indications that HS [hypertonic saline] might be superior to
mannitol in the treatment of TBI [traumatic brain injury]-related
raised ICP [intracranial pressure]"; however, "there are insuLicient
data to reach a definitive conclusion, and further trials are
warranted" (Schwimmbeck 2019). Authors of Gu 2019 synthesised
12 RCTs including those excluded for reasons mentioned above.
Searches did not capture Kumar 2019 or Patil 2019. Once again,
authors found a benefit that was not statistically significant for
intracranial pressure control with hypertonic saline as compared to
mannitol, but not enough to "lend a specific recommendation to
select hypertonic saline or mannitol as a first-line [treatment]"; all
other outcomes (including function and mortality) were "close".
In 2018, the European Society of Intensive Care Medicine (ESICM)
reported the consensus and clinical practice recommendations
on fluid therapy in neuro-intensive care patients (Oddo 2018).
ESCICM recommendations in the area of hyperosmolar fluids
for the management of elevated intracranial pressure guidelines
are consonant with our findings, stating, "we suggest the
use of mannitol or hypertonic saline solutions for reducing
increased intracranial pressure (weak recommendation)". A weak
recommendation was made when votes in favour or against (a mix
of strong and weak options) reached the 80% threshold.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We identified six trials suitable for inclusion in this review; all
compared a type of hypertonic saline with mannitol or mannitol
combined with glycerol; all evidence was of low or very low quality.
Trial authors noted that where immediate benefits of hypertonic
saline are suggested, they do not translate into long-term benefit.
Therefore at present, there is not suLicient evidence to enable
conclusions to be drawn about the eLicacy and safety of hypertonic
saline versus mannitol or other intracranial pressure-lowering
agents in the management of acute traumatic brain injury.
Implications for research
Carefully planned, high-quality randomised controlled trials are
warranted. We are concerned that searches of trials registers for this
review have revealed several terminated trials in this field, but are
pleased also to have identified an ongoing trial of adequate size
(Characteristics of ongoing studies).
Future investigators should consider implications of such
experiences. The following factors are relevant.
• Due to the diLerent definitions of 'uncontrolled intracranial
pressure' within identified trials and important diLerences
in reporting intracranial pressure changes from baseline, a
widely uniform definition for raised intracranial pressure and
intracranial pressure control is necessary. Recently, ESCIM have
suggested using a predefined trigger for starting osmotherapy
to treat elevated intracranial pressure, and they also suggest
using an intracranial pressure threshold above 25 mmHg,
independent of other variables, as a trigger for starting
osmotherapy to reduce intracranial pressure (Oddo 2018).
• Consideration should be paid to assessing optimal
concentration and infusion time of any intracranial pressure-
lowering agent.
• Investigators should collect and report data on types of
traumatic brain injury experienced by participants (e.g.
extradural haematoma, diLuse axonal injury)
• To test the eLect of hypertonic saline on death and neurological
recovery for acute traumatic brain injury but not just on
intracranial pressure control, longer-term follow-up than most
of the published trials in this area currently provide, is essential.
• Trials must be pre-registered and transparent, and reasonably
detailed protocols should be made available. Failure to do so
will, in future, result in exclusion of data from this review, in
accordance with Cochrane Injuries' policies (CIG 2015).
• Results of trials should be reported according to CONSORT
(Moher 2010).
• Failure to generate a truly informative sample size is an
ethical as well as a procedural problem. To combat diLiculties
in recruitment and attaining a necessary sample size, the
possibility of multicentre trials could be considered.
• Acknowledging obvious recruitment diLiculties within this field,
in order not to waste valuable data from persistent 'mixed
population' trials, investigators could be encouraged to report
outcomes disaggregated by type of neurological complaint, for
example, stroke or traumatic brain injury.
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Methods Design: parallel, RCT (2 sites)
Setting: ICUs in university hospitals in Bordeaux, France, and in Haifa, Israel
Recruitment period: June 2002-June 2003
Maximum follow-up: 6 months
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Participants 56 people (age > 16 years) with severe TBI (GCS ≤ 8) eligible for enrolment into the trial. Of these, 9 were
excluded, either because of ICP < 15 mmHg (n = 7) or serum osmolarity > 320 mOsm/L on admission (n
= 2)
Inclusion criteria: participants with "TBI severe enough to justify ICP monitoring and mechanical ven-
tilation under sedation with a Glasgow Coma Scale (GCS) score... of ≤ 8 at the time of admission" (Cot-
tenceau 2011, p 2004).
Exclusion criteria: being < 16 years of age; previous history of cerebral vascular disease; bilateral fixed
dilated pupils on admission; hypovolaemic shock
Baseline demographics
Age: mean of 42.7 years (SD 19.9) in the HTS group; mean of 36.1 years (SD 16.8) in the MTL group
Gender: (F/M): not reported
Severity: median admission GCS score: 5 (range 4-7) HTS group, 7 (range 5-8) in the MTL group
N randomized: 47 (HTS, n = 22; MTL n = 25)
N for whom data analysed for ICP: this number varied as number of ICP elevations decreased after
day 3. Trial authors report data for each of the 1st 3 days, until the point where values are available for
< 50% of either group. The last data (day 3) are for 24 participants (HTS = 11, MTL = 13)
N for whom GOS data analysed at 6 months: 6 deaths occurred in each group; these formed part of
the GOS categories. Data were available for the full sample (47; HTS, n = 22; MTL, n = 25)
Interventions Quote: "Assessment of patients was initiated prior induction of hyperosmolar therapy in presence of
ICP elevation above 15 mm Hg. Although ... lower than the 20mm Hg threshold quoted in the Guide-
lines for the Management of Severe TBI .... this threshold was chosen in accordance with the manage-
ment protocols of both participating centers and was consistent with clinical evidence showing that
ICP > 15 was one of the five independent factors associated with death following TBI ....Whenever ap-
propriate, patients received equiosmolar infusions of either..."
Intervention: HTS 7.5% (2 mL/kg; n = 22), delivered IV within 20 min
or
Comparator: MTL 20% (4 mL/kg; n = 25)
Quote: "As long as ICP remained elevated and monitored, all patients had a daily evaluation during
which a baseline assessment was followed by two additional tests performed at 30 and 120 min after
administration" (Cottenceau 2011, p 2004).
Outcomes Outcomes included (in hospital):
• ICP
• systemic and cerebral haemodynamics
• cerebral metabolism
• biochemical effects of hyperosmolar therapy
At 6 months:
• neurological outcome (GOS)
Notes Trial authors note their focus differs from others, i.e. "we aimed to comparatively assess the effect of
HTS and MTL, not only on ICP and neurological outcome but also on indices of cerebral blood flow
(CBF) and metabolism" (Cottenceau 2011 p 2004).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A computer-generated random-number table was used to assign
each consecutive envelope to receive a sheet indicating either MTL or HTL
Cottenceau 2011  (Continued)
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Low risk Quote: Before the trial, "30 opaque envelopes in each hospital had been pre-
pared and numbered sequentially....Envelopes were then sealed.... The sealed
envelopes were opened sequentially throughout the study when a patient ful-











High risk Correspondence with trial author in 2015. Quote: "at the acute phase where
the team was well aware of the regimen" (6 May 2015).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Correspondence with trial author in 2015. Quote: "as for the outcome, it was
assessed in both centers by blinded medical staL during follow-up visits or by




Low risk Outcome data are reported in full for ICP for as long as a reasonable number of
participants require it (day 3).
Selective reporting (re-
porting bias)
Unclear risk Correspondence with trial author in 2015. Quote: "the protocol is not of reach
after such a long time" (Soustiel 2015)
Other bias Unclear risk Authors note that "Comparative analysis of neurological outcome at 6 months
did not disclose any significant difference between the two groups. Although
there was a statistical trend suggestive of a better outcome in patients in the
MTL group, similar differences found in the CMRO2 [cerebral metabolic rate of
oxygen] values and GCS scores on admission between the two groups proba-
bly indicated some asymmetry in the degree of severity of injury and account-





Methods Design: Parallel, RCT
Setting: 2 ICUs at the same hospital in Grenoble, France
Recruitment period: October 2002-June 2005
Maximum follow-up: 2-h trial period
Participants A total of 20 stable patients with a sustained ICP of > 20 mmHg secondary to TBI (n = 17) or stroke (n =
3) were recruited.
Inclusion criteria: "Patients were included if they were aged 18 yrs and had sustained elevated ICP of
20 mm Hg for 10 mins, not related to procedural pain. They had to be mechanically ventilated and in
stable conditions for 2 hrs before the trial, as defined by the following criteria: MABP of 80 mm Hg, PaO2
of 80 mm Hg, PaCO2 of 45 mm Hg, serum osmolality ranging between 280 and 320 mOsm/kg, and body
temperature of 38.0°C" (Francony 2008, p 796).
Exclusion criteria: "Patients were excluded if they had any of the following criteria: an imminent cra-
nial or extracranial surgery, a previous decompressive craniectomy, a leakage or a drainage of cere-
Francony 2008 
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brospinal fluid, unstable respiratory and hemodynamic conditions, oliguric renal failure, hemoglobin
content of 100 g/L, serum osmolality of 320 mOsm/kg, the use of mannitol or HSS in the previous 6 hrs,
or a concomitant use of thiopentone." (Francony 2008, p 796).
Baseline demographics
Age: mean of 37 years (SD 16) in the HTS group; mean of 43 years (SD 11) in the MTL group
Gender: (F/M); 2:8 in the HTS group; 1:9 in the MTL group
Severity: mean GCS at baseline 8 (SD 2) HTS group, 7 (SD 2) in the MTL group
N randomized: 20 (HTS = 10; MTL = 10)
N for whom ICP data analysed: 20 (HTS = 10; MTL = 10)
Interventions Prior to the intervention, if the patient "met the inclusion criteria, a static cerebral autoregulation test
was performed because the response to osmotherapy may differ according to the pressure autoregula-
tion status.... After this test, the patient was assigned ...to receive... " either:
Intervention: a single equimolar infusion (255 mOsm dose) of 100 mL of 7.45% HTS in 20 min of admin-
istration via the central venous catheter
Comparator: a single equimolar infusion (255 mOsm dose) of 20% MTL in 20 min of administration via
the central venous catheter
"No therapeutic intervention (e.g., nursing procedure, manipulation of ventilatory variables, changes
in vasoactive support and in sedative drug regimens) was allowed during the experiment, except the
administration of 6% hydroxyethyl starch solution ... if MABP decreased 10% from baseline" (Francony
2008, p 796).
Outcomes During a trial period of 120 min, the following were measured:
• ICP
• arterial BP
• cerebral perfusion pressure
• blood flow velocities of middle cerebral artery using continuous transcranial Doppler
• brain tissue oxygen tension
• serum sodium and osmolality
• urine output
"Clinical and biological variables (blood gases, arterial pH, serum osmolality, hemoglobin) were col-
lected at baseline (reference time, T0) and repeated every 30 mins after the start of infusion (T30, T60,
T90) until the end of the study period (T120). Blood levels of sodium, chloride, glucose, and creatinine
were collected at T0 and at T120" (Francony 2008, p 796).
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the patient was assigned by randomization using sealed, numbered
envelopes" (Francony 2008, p. 796)
Allocation concealment
(selection bias)
Low risk Quote: "The patient was assigned by randomization using sealed, numbered





Low risk Participants had severe brain injury with sustained elevated ICP of > 20 mmHg
and therefore had reduced cognitive function.
Francony 2008  (Continued)
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High risk Quote: "The two treatments were of different volumes, it was not possible to
blind their administration" (Francony 2008, p. 796)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Objective outcomes such as laboratory measures or death are unlikely to have




Low risk Complete outcome data were reported (the trial lasted 120 minutes).
Selective reporting (re-
porting bias)
Low risk Following correspondence with the trial author in 2015, we obtained a copy of
the trial protocol. It is clear that the 2002 protocol focused on cerebral blood
flow and metabolism, which were adequately described.





Setting: ICU setting in a university hospital in Halle, Germany
Recruitment period: February 2003-August 2004
Maximum follow-up: end of stay in the ICU
Participants 40 "neurosurgical patients at risk of increased ICP" were recruited; 8 did not receive medication as ICP
threshold of 20 mmHg was not met; of the remaining 32, only a minority (n = 10) had TBI.
Inclusion criteria: "Age >18 years, severe brain damage (Glasgow Coma Score <8) with cerebral edema
– visualized by CT scan and continuous monitoring of ICP".
Exclusion criteria: "elevated ICP due to space-occupying lesions with indication for neurosurgical in-
tervention (e.g. bleeding, hydrocephalus), severe renal failure, metabolic disorders, initial serum sodi-
um >150 mmol/l and initial serum osmolarity >320 mosm/kg" (Harutjunyan 2005, p R531).
Baseline demographics
Age: mean of 47 years (SD = 16 years) across both groups
Gender: 17 men, 15 women (8/9 F/M in HTS/HES Group; 7/8 in MTL group)
Severity: GCS at baseline 6 ± 1.3 HTS/HES group, 5.8 ± 1.4 MTL group
N randomized: 32 (HTS/HES = 17; MTL = 15). Of these, 6 in HTS/HES group had TBI and 4 in MTL group)
N for whom ICP data analysed: 32 (HTS/HES = 17; MTL = 15)
Interventions A standard treatment protocol was followed (details of which appear Harutjunyan 2005, p R531). "All
patients were intubated and received pressure-controlled mechanical ventilation .... Care was taken to
keep the arterial partial oxygen pressure above 15 kPa, the hemoglobin concentration above 5.5 mmol/
l and the CPP above 70 mmHg. If necessary, blood pressure was supported with vasopressor thera-
py. Blood glucose was adjusted to values between 6–8 mmol/l by continuous application of human
insulin. Patients' core temperature was measured via the bladder, with a target temperature of 36.0–
37.0°C. ....Analgosedation and continuous patient monitoring were managed ....Analgosedation at days
1–4 was performed using propofol and sufentanil or remifentanil. Thereafter, midazolam and sufen-
tanil were administered. The standard monitoring ... An increase in ICP was treated first by deepening
the sedation and analgesia by titrating the medication and adjusting to adequate ventilator settings.
If ICP exceeded the 20 mmHg threshold for more than 5 min, the study medication ... was infused via
Harutjunyan 2005 
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the central venous line using an automated infusion system at a defined infusion rate. The infusion was
stopped when ICP was reduced to <15 mmHg, defined as the treatment goal."
Intervention: 7.2% HTS/HES (200/0.5) 6% by infusion
Comparator: MTL 15%, by infusion
"However, in the case of sustained ICP problems (ICP >15 mmHg or CPP <70 mmHg) after these mea-
sures, bolus applications of thiopentone (maximum single bolus: 5 mg/kg) were allowed. In these pa-
tients, the possibility of a space-occupying lesion was excluded by CT scan."







At the end of stay in the ICU, the following were measured:
• duration of time in ICU
• mortality
Notes Trial authors note their focus differs from others, i.e.: "The substantial difference in the design of the
present and a comparable study is the fact that we did not administer a fixed total dose, but infused
the study medication at a defined infusion rate until ICP decreased to <15 mmHg, the primary goal of
our treatment. No clinical study has so far identified an exact dose-effect relationship for hypertonic
saline." (Harutjunyan 2005, R537)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The random code for group assignment was generated by comput-
er" (Harutjunyan 2005, p R532)
Allocation concealment
(selection bias)





Low risk All participants had GCS score of < 8 and therefore had reduced cognitive func-
tion at the time of admission; outcome assessment was not long-term, so par-





High risk There is no indication that the treating physicians were blind to the treatments
given, as the time of treatment and doses given were different between trial
groups.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Objective outcomes such as laboratory measures or death are unlikely to have




Low risk A total of 40 neurosurgical patients were recruited and randomised to receive
either 7.2% HTS/HES 200/0.5 or MTL 15%. Only 32 participants were evaluated
since in 8 participants, ICP did not exceed 20 mmHg,therefore no trial medica-
tion was administered. No relevant clinical characteristics were revealed in the
Harutjunyan 2005  (Continued)
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8 participants not undergoing osmotic therapy. Full data were available for the
32 eligible by reason of exceeding 20 mmHg.
Selective reporting (re-
porting bias)
Unclear risk This trial was retrospectively registered in 2005, the year of its publication
(ISRCTN62699180). Although expected outcomes are present, in the absence
of a published protocol or prospective trial registration, assessment of selec-
tive outcome reporting must remain as "unclear."
Other bias High risk For the purposes of this review question, this trial's data must be considered
at high risk of bias because only a minority of participants had suffered a TBI;
a situation further complicated by acknowledged baseline imbalances (trial
authors note that "the clinical values in both groups were not normally distrib-





Setting: ICU of a tertiary neurosurgical center, Bangalore, India
Recruitment period: May 2008 to unknown date
Maximum follow-up: 6 months
Participants Inclusion criteria: participants with severe TBI; aged 15-70 years; to be enrolled into the trial within 24
h of injury
Exclusion criteria: people with GCS score of 3 and absent brainstem reflexes; pregnant women; those
with spinal cord injury or multiple systemic injuries
Baseline demographics
Age: mean of 27 years (SD 8) in the HTS group; mean of 31 years (SD 13) in the MTL group
Gender: (F/M); 1:8 in the HTS group; 1:9 in the MTL group
Severity: mean admission GCS score post-resuscitation median 4 (range 4-5) in the HTs group and 5
(range 4-6) in the MTL group
N randomized: 38 (HTS, n = 18; MTL n = 20)
N for whom data analysed at 6 days: 30 (HTS, n = 15; MTL, n = 15) had ICP/CPP data available for the
main data collection period (6 days). Of the rest, 4 died before day 6 and in 4, ICP monitoring was dis-
continued after < 6 days as clinical status had improved.
N for whom GOS and mortality data analysed at 6 months: 22 (HTS, n = 12; MTL, n = 10)
Interventions Prior to treatment "All patients were managed in the ICU according to the Brain Trauma Foundation
guidelines [2007] .... The aim of the therapy was to maintain the ICP below 20 mmHg and CPP above 50
mmHg. Any spontaneous ICP increase to >20 mmHg qualified as an ICH episode. If an ICH episode oc-
curred despite adequacy of sedation, ventilation and head position, CSF was drained until it stopped
flowing spontaneously as a first line intervention. If the ICP remained elevated (>20 mmHg for >10 min-
utes) in spite of CSF drainage (until the CSF egress ceased), patients received osmotic therapy" (Jagan-
natha 2016, p 69) as follows:
Intervention: 3% HTS, in an equiosmolar dose infused as a bolus through a central venous catheter
over 5 min
Comparator: 20% MTL, in an equiosmolar dose infused as a bolus through a central venous catheter
over 5 min
Subsequently, "If the first dose of the osmotic agent failed to decrease the ICP to below 20 mmHg, a
maximum of three doses of the same drug were administered. If the ICH persisted, hyperosmolar ther-
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apy was considered a failure and thiopentone, propofol, or moderate hyperventilation (PaCO2 = 30
mmHg) were instituted. As per the Brain Trauma Foundation guidelines, decompressive craniectomy
was considered after exhausting general measures, CSF drainage, osmotic therapy and metabolic sup-
pression. Hyperosmolar therapy was temporarily suspended if serum sodium increased to > 160 mmol/
dL or if serum osmolality increased to >320 mosm/kg. Inotropes/vasopressors (dopamine, adrenaline
and noradrenaline) were administered as and when required to maintain CPP. A CT scan of the head
was repeated at 24 hours and 5 days post-trauma, and whenever the patient suffered a neurological
deterioration. The ICP catheter was leP in situ for 6 days. The catheter was removed earlier if the pa-
tient started obeying commands or the ICP was maintained <20 mmHg for 24 hours."
Outcomes For each bolus of the hyperosmolar agent administered over 6 days, the following were recorded:
• ICP (initial ICP; lowest ICP achieved following the hyperosmolar agent; time required to achieve ICP
< 20 mmHg)
The following outcomes were also assessed in hospital:
• duration of ICU stay
• duration of hospital stay
• in-hospital mortality
At 6 months, the following was measured:
• GOS scores
Notes Trial authors note their focus differs from others, i.e.: "Overall, the literature is centered on efficacy in
individual episodes of ICH than the sustenance of ICP control during the acute phase of TBI, which is
more relevant to the outcome. Our study differs from the other studies in this important respect" (Ja-
gannatha 2016, p. 71)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Each patient was recruited into the mannitol or HTS group based on a










Low risk Participants had severe brain injury with sustained elevated ICP of > 20 mmHg





High risk There is no indication that the treating physicians were blind to the treatments
given.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Objective outcomes such as laboratory measures or death are unlikely to have




High risk For the outcome of ICP, there appear to be no data missing for reasons oth-
er than participants' not having ICP assessed due to improvement in status,
or to their deaths. In the longer term however, of the 30 who leP hospital, 8
were lost to follow-up, as explained by trial authors in a personal communica-
tion (Jagannatha 2017). Data were "based on telephonic interview with the pa-
Jagannatha 2016  (Continued)
Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury (Review)









Cochrane Database of Systematic Reviews
tient/ patients relative. Unfortunately due to various reasons (wrong phone
number, no one to answer the ringing phone, change of number) we could not
collect the data for 8 patients in total."
Selective reporting (re-
porting bias)
Unclear risk This trial was retrospectively registered in 2016. Enrolment appears to have
commenced in May 2008 (CTRI//04/006829 2016). Although expected out-
comes are present, in the absence of a published protocol or prospective trial
registration, assessment of selective outcome reporting must remain as "un-
clear."
Other bias Unclear risk Trial authors note that some "methodological issues need to be taken into ac-
count when interpreting our results. ... Though we intended to recruit consec-
utive patients, some patients were excluded for logistic reasons. The GCS at in-
clusion of the patient into the study was much lower in this study compared
with other studies, with a median of 5 and 4 (eye opening and motor scores) in
the mannitol and HTS groups, indicating a more severe injury. Some of the pa-
tients in the study underwent surgery, which might have conferred some ben-
efit in terms of ICP reduction. The patients were controlled for GCS at the time
of inclusion and not the type of lesion on CT scan. The occurrence of twice the
number of subdural hematomas in the mannitol group (15 versus seven) may
have introduced a bias. Subdural hematomas by virtue of being a pathologi-
cally more severe form of injury may have necessitated a higher number of hy-
perosmolar boluses in the mannitol group. The groups, however, were compa-
rable with respect to the overall radiological profile and findings at surgery. Al-
so, to our surprise, even in the operated patients, the initial reduction of ICP
was followed by a progressive increase over time. Poor glycemic control in the
mannitol group may also have influenced the outcome in these patients. The
number of patients in the study was small and this limited our outcome analy-




Methods Design: parallel, equivalence RCT (single site)
Setting: ICU of a tertiary neurosurgical centre in Bangalore, India
Recruitment period: January 2012-June 2014
Maximum follow-up: 6 months
Participants 50 children were assessed; 30 met eligibility criteria (20 were excluded with reasons given). All children
underwent initial resuscitation, evaluation and treatment for TBI as required; CT scan studies on ad-
mission were analysed using Marshall criteria (Marshall 1992)
Inclusion criteria: children in age group 1-16 years with severe TBI, defined as post-resuscitation Pedi-
atric GCS of ≤ 8, and presenting within 24 h of trauma
Exclusion criteria: having a GCS of 3; absent brain stem reflexes; systemic injuries requiring immediate
treatment; clinical evidence of significant spinal cord injuries; or presenting > 24 h after injury
Baseline demographics
Age: a mean for age is not reported. Trial authors report no significant difference between groups.
There is a typographical error in the total number for the ranges of age groups, but the disaggregated
totals add up to 30, and are reported as follows: of eligible children admitted to the trial, 14 children
were aged 1-5 years; 7 children age 6-10; 9 children aged 11-16
Gender: 12 girls, 18 boys; 6:14 in the HTS group; 6:16 in the MTL group
Severity: post resuscitation GCS means and SDs were given by group. These were 7.4 (SD = 0.9) in the
HTS group and 6.6 (SD=1.1) in the MTL group.
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Data on manner of injury (road accidents, falls); pupillary reaction to light; head CT findings; interval
between injury and insertion of EVD, duration of monitoring, duration of ventilation, duration of ICU
stay, and duration of hospital stay, were also collected
N randomized: 30 (HTS, n = 14; MTL n = 16)
N for whom data analysed for ICP/GOS data analysed: trial authors report no missing data; data
available for the full sample (HTS, n = 14; MTL, n = 16)
Interventions "The aim of the therapy [ICP monitor setup and treatment, protocol described] was to maintain the ICP
below 15 mmHg in children between 1 and 10 years of age and 18mmHg in children age 11–16 years
of age [7, 8]. When the ICP remained raised more than the cutoff value for more than 5 min in the ab-
sence of noxious stimuli like suction, positioning, etc., it qualified as an intracranial hypertensive (ICH)
episode. For an ICH episode, the EVD was opened to drain CSF until it stopped flowing or up to 20 cc re-
lease of CSF whichever is first...After successful insertion of EVD and ICP monitoring, the patients were
randomized to receive one of the interventional agents. ...[which]were administered if ICP remained
persistently above the cutoff value for more than 5 min in spite of CSF drainage. The ICU staL informed
each episode of raised ICP to one of the investigators (AK or DS), who was available at bedside before
initiating treatment for reduction of ICP. The investigator personally documented ICP before initiation
and after completion of treatment, and measured reduction in ICP for each dose of medication" (Ku-
mar 2019 p 1000)
Intervention: equiosmolar dose of 3% HTS (1027 mOsm/L) as a bolus of 2.5 mL/kg through the central
venous line over a period of 5 min (n = 14 participants)
Comparator: equiosmolar dose of 20% MTL (1098 mOsm/L) as a bolus of 0.5 g/kg (2.5 mL/kg; n = 16
participants)
"If the ICP did not decrease even after two consecutive doses of the hyperosmolar agent, it was consid-
ered refractory to therapy" (Kumar 2019 p 1000)
Monitoring of active treatment appears to have continued for 5-6 days
Outcomes Primary outcome: mean reduction of ICP - defined as "the difference between ICP value before admin-
istering hyperosmolar agent and lowest ICP value after completion of bolus for each dose. The mean
reduction in ICP was obtained by summing the difference in ICP values before and after treatment di-
vided by number of doses during the entire period of ICP monitoring" (Kumar 2019, p 1001).
Secondary outcome:
• neurological outcome (GOS) At 6 months. This was modified for children by replacing the outcome of
'work' with 'activity or scholastic performance' for age and pre-injury status of child (Beers 2012)....
The functional outcome was analyzed as death or survival in vegetative state versus survival with or
without disability" (Kumar 2019 p 1001, emphasis added - this is not the conventional 'cut-oL' for
'poor' or 'good' outcome)
Other data collected included:
• ICP and ICP-related data including mean ICP, MAP, and CPP for each day, number of episodes of raised
ICP requiring CSF releases, volume of CSF drained, and number of doses of osmotic drugs required
per day
• duration of monitoring, duration of ventilation, duration of ICU stay, and duration of hospital stay
• mean values of serum glucose, sodium, creatinine
• number of participants requiring isonotropes
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Kumar 2019  (Continued)
Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury (Review)









Cochrane Database of Systematic Reviews
Random sequence genera-
tion (selection bias)
Low risk Quote: "The randomization was done through computer-generated random









Low risk Participants had brain injury and neither they nor parents/carers were likely to





High risk There is no indication that the treating physicians were blind to the treatments
given, and the trial is described as "single blind".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Trial authors report that "The person who assessed outcome was blinded for




Low risk For the outcome of ICP, there appear to be no data missing.
Selective reporting (re-
porting bias)
Unclear risk Trial authors report that this trial was registered with Clinical Trials Registry of
India (REF/2015/03/008696). The date suggests retrospective registration.
Other bias Unclear risk Authors note that "The limitation of our study was small sample size. ...For ad-
equate power of study, a large multicenter study is warranted. The present un-
derpowered study cannot generate a good class of evidence but demonstrates
the feasibility of such studies at a larger scale. The second limitation was use
of hyperosmolar therapy as second tier treatment after failure of CSF drainage
to reduce the ICP. The EVD, when available, is recommended prior to hyperos-
molar therapy.... The EVD as an initial treatment may dilute the effect of hyper-
osmolar therapy. It is not known, whether there will be any difference in ICP
reduction between mannitol and hypertonic saline if any of these agents are
administered as first-line therapy. Many centers do not use EVD for ICP moni-
toring. When ICP monitoring is done using parenchymal sensor, option of CSF
drainage is not available, and true effect of hyperosmolar therapy can be as-
sessed. The third limitation was that we did not measure time to peak effect
and duration of effect, cerebral blood flow, cerebral tissue oxygen, cerebral
metabolism, cerebral injury biomarkers, cerebrospinal compliance, and pres-
sure reactivity. The multimodal monitoring is labor intensive, and is not avail-




Methods Design: parallel, 3-armed RCT (single site)
Setting: ICU in a department of neurosurgery at a teaching hospital in Indore, Madhya Pradesh, India
Recruitment period: 2015-2017
Maximum follow-up: 1-h observation period following the treatment goal of reduction of ICP below 15
mmHg (after a single bolus)
Patil 2019 
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Participants A total of 120 participants with isolated severe TBI due to road traffic accidents were recruited.
Inclusion criteria: "After assessing the Glasgow Coma Scale (GCS), computed tomography of the head
was performed to rule out the need for immediate surgery. Patients were included if they were aged 18
years, GCS 8, and had sustained elevated ICP of >20 mm Hg for more than 5 minutes"
Exclusion criteria: "... imminent cranial or extracranial surgery Previous decompressive craniectomy
Leakage or drainage of cerebrospinal fluid Polytrauma Oliguria, renal failure Hemoglobin <8 g/L Serum
osmolality of >320 mOsm/L. The use of mannitol or HTS in the previous 6 hours." (Patil 2019 p e222)
Baseline demographics
Age: mean was given as 38.42 (+/-15.5 years). The range was 18-75 years.
Gender: (F/M); not reported
Severity: mean GCS at baseline reported as 6 (range 3-8) in the HTS group; 5 (range 3-7) in the MTL
group and 5 (range 3-6) in the combined MTL and glycerol group, BP also reported
N randomized: 120 (HTS = 40; MTL = 40; MTL plus glycerol 40)
N for whom ICP data analysed: not stated, but data presumed to be complete (assessments gathered
across 1 h): 120 (HTS = 40; MTL = 40; MTL plus glycerol 40)
Interventions At first- "Analgesia was provided to all the patients and if required sedation also provided in irritable
patients (dexmedetomidine). Vasoactive support (norepinephrine) was administered in hypotensive
patients. Insulin treatment was administered to maintain glycemia at <140 mg/dL. For each patient, a
set of variables was collected that included demographic characteristics data, initial GCS, and timing of
studied treatment. The ICP was continuously monitored by using an intracranial bolt..."
When ICP exceeded 20 mm Hg for a period of > 5 min, interventions comprised a single bolus dose of
one of the following:
Intervention: HTS 3% (n = 40); mean dose of 1.4 mL/kg (range 0.5-3.3); mean dose mL application 94
(range 38-234)
or
Comparator 1: MTL 20% (n =40); mean dose of 2.0 mL/kg (range 0.5-6.3); mean dose mL application
137 (range 40-422)
Comparator 2: MTL 10% plus 10% glycerol combination (n =40); mean dose of 1.7 mL/kg (range 1.6-4);
mean dose mL application 118 (range 44-302)
All treatments were "infused via the central venous line at a defined infusion rate, that is, 6 mL/minute
or 120 drops/minute (osmolarity of mannitol, mannitol plus glycerol combination, and 3% HTS are al-
most the same, ie, 1100 mOsm/L, 1049 mOsmo/L, and 1027 mOsm/L, respectively). The infusion was
stopped when ICP was reduced to <15 mm Hg, which was our treatment goal" (Patil 2019, e222).
Outcomes • ICP (goal of treatment was a reduction to ICP of < 15mm Hg). ICP was measured by the intracranial
bolt.
• Heart rate, MAP, ICP, and calculated CPP were continuously measured up to termination of infusion.
These were also measured
* 10 minutes after terminating infusion
* 30 minutes after terminating infusion
* 60 minutes after terminating infusion.
• Serum sodium level, hematocrit, serum osmolality were measured before and after treatment
• GCS was measured before and after the trial (at 60 min following infusion termination)
The lack of data collection on adverse events is mentioned as a trial limitation.
Notes This trial is not reported according to CONSORT/PRISMA. There is no flowchart; scant description of
methods. Baseline data including lesion type, gender, are unreported. All data are reported in ranges
(minimum-maximum). Mortality is not specifically reported although GCS (after a single bolus dose) is
Patil 2019  (Continued)
Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury (Review)









Cochrane Database of Systematic Reviews
reported. The paper states that recruitment took place 2015-2017, but submission of the present paper
was apparently made in 2016.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "All the patients were divided into 3 groups (40 in each group) using the
sealed envelope method of physical randomization" (Patil 2019, p e223)
Appears adequate although phrasing unusual
Allocation concealment
(selection bias)
Low risk Quote: "All the patients were divided into 3 groups (40 in each group) using the
sealed envelope method of physical randomization" (.Patil 2019, p e223)





Low risk Participants had severe brain injury with sustained elevated ICP of > 20 mmHg






High risk Agents were of different substances (or at different doses). Trial authors do not
report any blinding of those administering or collecting data.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk We have some concerns about the lack of information on assessment of GCS,
which was assessed alongside hematocrit, ICP, etc., to a maximum of 1 h, dur-
ing a period of nearly constant assessment. It is not stated who undertook this,




Low risk Complete outcome data were reported (the post-intervention data collection
period lasted 60 min)
Selective reporting (re-
porting bias)
Unclear risk Trial authors mention ethics approval, but not trial registration. Although most
expected outcomes are present, in the absence of a published protocol or
prospective trial registration, assessment of selective outcome reporting must
remain as 'unclear'
Other bias Unclear risk Trial authors comment that they did not assess any complications associated
with the placement of the subdural bolt used for measuring ICP.
Patil 2019  (Continued)
BP: blood pressure; CBF: cerebral blood flow; CPP: cerebral perfusion pressure; CSF: cerebrospinal fluid; CT: computerised tomography
scan; EVD: external ventricular drain(age); GCS: Glasgow Coma Scale; GOS: Glasgow Outcome Scale; HES: hydroxyethyl starch; HTS:
hypertonic saline; ICP: intracranial pressure; ICU: intensive care unit; IV: intravenous; MAP/MABP: mean arterial [blood] pressure; MTL:
mannitol; RCT: randomised controlled trial; SD: standard deviation; SpO2: peripheral capillary oxygen saturation; TBI: traumatic brain
injury
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Battison 2005 This is a prospective, cross-over, pilot trial.
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Study Reason for exclusion
Bourdeaux 2011 Participants received doses of HTS or sodium bicarbonate in a random order, some having both.
This may result in cross-over effects between treatments.
Du 2017 This trial was excluded because there was no defined trigger for starting hyperosmotherapy to re-
duce ICP, and mannitol was administered every eight hours.
Hong 2017 This trial was excluded due to unreliable methods (HTS or other ICP-lowering agents were adminis-
tered by time but not according to ICP monitoring).
Huang 2014 This is a randomised clinical trial with a cross-over design.
Huang 2015 This trial was excluded for questionable sequence generation; there was no reporting on outcomes
of interest to this review.
Ichai 2009 Sodium lactate was used to decrease the raised ICP. Sodium lactate differs fundamentally from
sodium chloride; infusion of sodium lactate in TBI decreases the occurrence of raised ICP. The ab-
sence of significant modification of plasma osmolarity does not support a pure osmotic effect of
sodium lactate.
Jafari 2018 This trial was excluded because it assessed the effects of adding furosemide to 1 of 2 groups both
receiving HTS.
Jiang 2018 RCT. Excluded because of ineligible comparator (there were 3 arms, all of HTS, in the same concen-
tration but delivered at different speeds (6 mL/3 mL/2 mL per h).
Jin 2018 Excluded due to doubts about sequence generation and apparently unreliable data. We were un-
able to contact trial authors for clarification.
Li 2018 Excluded due to unreliable data and methods (there is an error in the judgement of P value).
Liang 2013 Excluded due to unreliable data and methods (incorrect 'T' values, questionable sequence genera-
tion). We were unable to contact trial authors for clarification.
Liu 2018 Excluded due to unreliable methods (HTS or other ICP-lowering agents were administered by time
but not according to ICP monitoring).
Mei 2016 Excluded due to unreliable data and methods (incorrect 'T' values, questionable sequence genera-
tion). We were unable to contact trial authors for clarification.
NCT01028339 Appeared to meet inclusion criteria but according to the clinicaltrials.gov record it has been "termi-
nated. (No patients enrolled during 2 years)".
NCT01108744 This trial met inclusion criteria but according to the clinicaltrials.gov record was "...withdrawn prior
to enrolment. Timeline to consent prior to intervention start was unfeasible".
NCT01111682 This trial met inclusion criteria but according to the clinicaltrials.gov record was "...terminated. (A
significant reduction in head injuries coupled with more frequent use of craniectomy reduced the
number of potential subjects)".
NCT01215019 This trial met inclusion criteria but according to the clinicaltrials.gov record was "...withdrawn prior
to enrolment. (Lack of funding; no subjects enrolled)".
Ni 2018 Excluded due to unreliable data and methods (e.g. no clear definition of ICP).
Polushin 2009 This is a randomised clinical trial with a cross-over design.
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Study Reason for exclusion
Roquilly 2017 This planned RCT is measuring continuous hyperosomolar therapy (HTS) in participants with TBI vs
standard care (which is unlikely to include other ICP-lowering agents).
Sakellaridis 2011 This is a prospective, cross-over, pilot trial.
Shu 2015 Excluded due to unreliable data and methods (incorrect 'T' values, questionable sequence genera-
tion). We were unable to contact trial authors for clarification.
Upadhyay 2010 The sequence generation was described (quasi-randomisation). The included participants were
200 children with increased ICP of various different aetiologies, of whom only 14 had TBI. Compar-
ison of average reduction of MAP at defined intervals was performed to indirectly assess reduction
in ICP.
Wang 2017 This trial was non-therapeutic in nature, measuring only coagulation.
Yang 2019 This trial was excluded because it compared two different doses of HTS (7.5% HTS (4 ml/kg) and
3% HS treatment (4 ml/kg)).
Zhang 2014 Excluded due to unreliable data and methods (incorrect 'T' values, questionable sequence genera-
tion). We were unable to contact trial authors for clarification.
Zhang 2015 Excluded due to unreliable data and methods (incorrect 'T' values, questionable sequence genera-
tion). We were unable to contact trial authors for clarification.
Zhang 2018 Excluded due to unreliable methods (HTS or other ICP-lowering agents were administered by time,
but not according to results of ICP monitoring).
HTS: hypertonic saline; ICP: intracranial pressure; MAP: mean arterial pressure; RCT: randomised controlled trial; TBI: traumatic brain
injury;
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Prospective, randomised trial
Participants 20 consecutive patients with head trauma and persistent coma who required infusions of an os-
motic agent to treat episodes of ICP resistant to well-conducted standard modes of therapy.
Interventions Participants were randomly assigned to receive isovolume infusions of either 7.5% HTS solution (n
=10) or 20% MTL (n =10).
Outcomes • Mean number and the duration of episodes of ICP/d during the trial period
• Mean number of osmotic solute infusions
• Rate of clinical failure
Notes The numbers quoted in the abstract and the main results in Table 2 were not the same. Direct con-
tact with the trial authors did not resolve this issue.
Vialet 2003 
HTS: hypertonic saline; ICP: intracranial pressure; MTL: mannitol
 
Characteristics of ongoing studies [ordered by study ID]
 
Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury (Review)









Cochrane Database of Systematic Reviews
Trial name or title Salt or Sugar (SOS) trial: hyperosmolar in traumatic brain injury
Methods RCT. Sample size intended to be 219 per group (638 in total)
Participants Target population
Adult patients (aged > 16 years) with severe TBI and raised intracranial pressure (ICP).
• Age > 16 years
• Admission to ICU following TBI
• ICP > 20 mmHg for > 5 min despite stage 1 procedures
• < 10 d from initial head injury




• Severe hypernatraemia (Na > 160 mmol/L)
Interventions 2 mL/kg bolus of 20% MTL
vs
2 mL/kg bolus of 3% HTS (or equivalent osmolar bolus)
Outcomes Primary outcome
• 1. Extended GOS-E measured at 6 months after randomisation
Secondary outcomes
• ICP control (during period of monitoring on ICU)
• Progression to stage 3 therapies
• which stage 3 therapies were required
• Organ support requirements
• Critical care length of stay
• Hospital length of stay
• Modified Oxford Handicap Score (mOHS) at hospital discharge
• GOS-E at 12 months
• Survival at hospital discharge, 3, 6 and 12 months
• Quality of life (EQ-5D-5L) at hospital discharge, 3, 6 and 12 months
• Serious adverse events
Health economic outcomes
• Costs and within-trial and lifetime cost-effectiveness from an National Health Service (UK) and
personal social services (PSS) perspective.
Starting date 1 June 2019-1 December 2023
Contact information Professor Gavin Perkins,University of Warwick
UK
G.D.Perkins@warwick.ac.uk
Notes Information above came directly from a 'Trial Summary Sheet' sent to review authors in March
2019; trial was then registered here: ISRCTN16075091 (apps.who.int/trialsearch/Trial2.aspx?Tri-
alID=ISRCTN16075091)
Salt or Sugar 2019 
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CT: computed tomography; GOS-E: Glasgow Outcome Scale-Extended; HTS: hypertonic saline; ICP: intracranial pressure; ICU: intensive
care unit; MTL: mannitol; RCT: randomised controlled trial; TBI: traumatic brain injury;
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Hypertonic saline versus mannitol





Statistical method Effect size
1 Mortality: short-term 2   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
1.1 Mortality within 6 days 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Mortality at discharge from ICU 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Mortality at discharge from hospital 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Mortality: 6 months 2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Mortality at 6 months' follow-up (avail-
able data for Jagannatha)
2 85 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.46, 1.55]
2.2 Mortality at 6 months' follow-up (worst
case for HTS data for Jagannatha)
2 85 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.66, 1.89]
2.3 Mortality at 6 months' follow-up (best
case for HTS data for Jagannatha)
2 85 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.38, 1.18]
3 GOS: poor outcome at 6 months (conven-
tional dichotomisation)
2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 GOS 6 months (available data Jagan-
natha)
2 85 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.82, 1.44]
3.2 GOS 6 months (worst case for HTS data
for Jagannatha)
2 85 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.97, 1.58]
3.3 GOS 6 months (best case for HTS data for
Jagannatha)
2 85 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.74, 1.24]
4 GOS: poor outcome at 6 months (death +
persistent vegetative state vs all other dis-
ability categories )
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
4.1 GOS: poor outcome at 6 months (uncon-
ventional dichotomisation)
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1.   Comparison 1 Hypertonic saline versus mannitol, Outcome 1 Mortality: short-term.
Study or subgroup HTS Mannitol Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
1.1.1 Mortality within 6 days  
Jagannatha 2016 3/18 1/20 3.33[0.38,29.25]
   
1.1.2 Mortality at discharge from ICU  
Harutjunyan 2005 7/17 9/15 0.69[0.34,1.39]
   
1.1.3 Mortality at discharge from hospital  
Jagannatha 2016 3/18 10/20 0.33[0.11,1.02]
Favours HTS 10000.001 100.1 1 Favours mannitol
 
 
Analysis 1.2.   Comparison 1 Hypertonic saline versus mannitol, Outcome 2 Mortality: 6 months.
Study or subgroup HTS Mannitol Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.2.1 Mortality at 6 months' follow-up (available data for Jagannatha)  
Cottenceau 2011 6/22 6/25 37.22% 1.14[0.43,3.02]
Jagannatha 2016 6/18 10/20 62.78% 0.67[0.3,1.46]
Subtotal (95% CI) 40 45 100% 0.84[0.46,1.55]
Total events: 12 (HTS), 16 (Mannitol)  
Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%  
Test for overall effect: Z=0.56(P=0.58)  
   
1.2.2 Mortality at 6 months' follow-up (worst case for HTS data for Ja-
gannatha)
 
Cottenceau 2011 6/22 6/25 37.22% 1.14[0.43,3.02]
Jagannatha 2016 10/18 10/20 62.78% 1.11[0.61,2.03]
Subtotal (95% CI) 40 45 100% 1.12[0.66,1.89]
Total events: 16 (HTS), 16 (Mannitol)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%  
Test for overall effect: Z=0.42(P=0.67)  
   
1.2.3 Mortality at 6 months' follow-up (best case for HTS data for Ja-
gannatha)
 
Cottenceau 2011 6/22 6/25 29.75% 1.14[0.43,3.02]
Jagannatha 2016 6/18 14/20 70.25% 0.48[0.23,0.97]
Subtotal (95% CI) 40 45 100% 0.67[0.38,1.18]
Total events: 12 (HTS), 20 (Mannitol)  
Heterogeneity: Tau2=0; Chi2=2.01, df=1(P=0.16); I2=50.23%  
Test for overall effect: Z=1.37(P=0.17)  
Test for subgroup differences: Chi2=1.7, df=1 (P=0.43), I2=0%  
Favours HTS 2000.005 100.1 1 Favours mannitol
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Analysis 1.3.   Comparison 1 Hypertonic saline versus mannitol, Outcome
3 GOS: poor outcome at 6 months (conventional dichotomisation).
Study or subgroup HTS Mannitol Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.3.1 GOS 6 months (available data Jagannatha)  
Cottenceau 2011 17/22 14/25 46.37% 1.38[0.91,2.09]
Jagannatha 2016 12/18 16/20 53.63% 0.83[0.56,1.23]
Subtotal (95% CI) 40 45 100% 1.09[0.82,1.44]
Total events: 29 (HTS), 30 (Mannitol)  
Heterogeneity: Tau2=0; Chi2=3.02, df=1(P=0.08); I2=66.92%  
Test for overall effect: Z=0.57(P=0.57)  
   
1.3.2 GOS 6 months (worst case for HTS data for Jagannatha)  
Cottenceau 2011 17/22 14/25 46.37% 1.38[0.91,2.09]
Jagannatha 2016 16/18 16/20 53.63% 1.11[0.85,1.46]
Subtotal (95% CI) 40 45 100% 1.24[0.97,1.58]
Total events: 33 (HTS), 30 (Mannitol)  
Heterogeneity: Tau2=0; Chi2=0.85, df=1(P=0.36); I2=0%  
Test for overall effect: Z=1.68(P=0.09)  
   
1.3.3 GOS 6 months (best case for HTS data for Jagannatha)  
Cottenceau 2011 17/22 14/25 40.23% 1.38[0.91,2.09]
Jagannatha 2016 12/18 20/20 59.77% 0.67[0.48,0.94]
Subtotal (95% CI) 40 45 100% 0.96[0.74,1.24]
Total events: 29 (HTS), 34 (Mannitol)  
Heterogeneity: Tau2=0; Chi2=7.31, df=1(P=0.01); I2=86.31%  
Test for overall effect: Z=0.32(P=0.75)  
Test for subgroup differences: Chi2=1.94, df=1 (P=0.38), I2=0%  
Favours HTS 200.05 50.2 1 Favours mannitol
 
 
Analysis 1.4.   Comparison 1 Hypertonic saline versus mannitol, Outcome 4 GOS: poor
outcome at 6 months (death + persistent vegetative state vs all other disability categories ).
Study or subgroup HTS Mannitol Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
1.4.1 GOS: poor outcome at 6 months (unconventional dichotomisation)  
Kumar 2019 2/12 3/13 0.72[0.14,3.61]
Favours HTS 5000.002 100.1 1 Favours mannitol
 
 
A D D I T I O N A L   T A B L E S
 
Study ID Cottenceau 2011 Francony 2008 Harutjun-
yan 2005
Jagannatha 2016 Kumar 2019 Patil 2019
Baseline
measures
           
Table 1.   Data collected within studies 
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  Demographic data
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Neurological con-
















           
  Fall in ICP (mean and
SD before infusion, af-
ter 30 min, after 120
min, comparisons
made using repeat-
ed measures model of
ANOVA)
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Table 1.   Data collected within studies  (Continued)
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  Numbers of ICP eleva-
tions during average
monitoring duration
of 3.7 to 3.8 days
    24 h mean ICP moni-
toring
ICP tracings  
        Time required to





        Duration of time ICP
was maintained at <
20 mmHg in a given
day
   
        'Effective' doses/'inef-
fective' doses (as re-
gards ICP)
Mean number of
doses per day; in-
stances of refracto-










           










        Barbiturate interven-
tion
Ionotropes  





           
Common
measures
MAP MAP MAP MAP   MAP
  CPP CPP CPP   CPP CPP
  CVP CVP        
    Heart rate Heart rate Heart rate   Heart rate
  Serum Na Serum Na Serum Na Serum Na   Serum Na
  Cerebral metabolic
rate of glucose (CMR-
Glc (mg/100 g/min))
Blood glucose   Blood glucose    
Table 1.   Data collected within studies  (Continued)
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Serum osmolality   Serum os-
molarity
    Fluid balance   Fluid balance    
  Haemoglobin Haemoglobin       Haemo-
globin
  Hematocrit   Hematocrit     Hemat-
ocrit
        Volume of CSF drained Volume of CSF
drained
 







           





       






Serum chloride SpO2      
  Blood urea nitrogen Serum creati-
nine
       
  Shear Rate          





       
    Brain tissue
oxygen tension
       
    Urine output
(vol)
       
    Arterial PH        











Table 1.   Data collected within studies  (Continued)
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In ICU, GCS score fol-
lowing interruption of
sedative drugs. Neuro-
logical outcome at 6











tality at 6 months








AVDGlc: Arterial jugular differences for glucose; AVDLct: Arterial jugular differences for lactate; AVDO2: Arterial jugular differences for
oxygen; CBF: cerebral blood flow; CMRGlc: cerebral metabolic rate of glucose; CMRLct: cerebral metabolic rate of lactate; CMRO2:
cerebral metabolic rate of oxygen; CPP: cerebral perfusion pressure; CSF: cerebrospinal fluid; CVP: central venous pressure; CT: com-
puted tomography; EVD: extraventricular drain; GCS: Glasgow Coma Scale; GOS: Glasgow Outcomes Scale; ICH: intracranial hyper-
tension;ICP: intracranial pressure; ICU: intensive care unit; MAP: mean arterial pressure; NICU: neuro-intensive care unit; PaCO2: par-
tial pressure of carbon dioxide in arterial blood; PaO2: partial pressure of oxygen in arterial blood; SAPS: simplified acute physiology
score; SD: standard deviation; SPO2 = peripheral oxygen saturation
Table 1.   Data collected within studies  (Continued)
 
 
A P P E N D I C E S
Appendix 1. Search Dec 2019 (English language sources)
Note. Amendments were made to update searches in 2017, including more sensitive list of terms for hypertonic saline solution and
hyperosmolar therapy. The searches were back-dated to accommodate these changes and records de-duplicated from the 2013 search
results. ThereaPer, 2018 and 2019 searches used the same terms.
Cochrane Injuries Group specialised register (SR-INJ)
#1 (((head or crani* or cerebr* or brain* or intra-cran* or intracran* or intra-cereb* or intracereb*) adj3 (haematoma* or hematoma* or
haemorrhag* or hemorrhag* or hernia* or bleed* or pressure or hypertensi* or oedema or edema or swell*))):TI,AB,KY AND SR-INJ:CC
#2 (((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or intracran* or intra-cereb* or
intracereb*) near (infarct* or injur* or trauma* or damag* or wound* or fracture* or contusion*))):TI,AB,KY AND SR-INJ:CC
#3 ((TBI or mTBI or sTBI) ):TI,AB,KY AND SR-INJ:CC
#4 (("subarachnoid h?emorrhage" or tSAH) ):TI,AB,KY AND SR-INJ:CC
#5 ((diLuse axonal injury or diLuse axonal injuries or persistent vegetative state or glasgow outcome scale or glasgow coma scale)):TI,AB,KY
AND SR-INJ:CC
#6 ((Glasgow adj3 (coma or outcome) adj3 (scale* or score*))):TI,AB,KY AND SR-INJ:CC
#7 (((midbrain or mid brain) NEXT syndrome)):TI,AB,KY AND SR-INJ:CC
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 (((hypertonic or hyper-tonic) AND (saline or salt or sodium chloride or NaCl))):TI,AB,KY AND SR-INJ:CC
#10 ((osmotherap* or "osmo* therap*" or "hyperosmo* therap*" or osmolar* or hyperosmolar*) ):TI,AB,KY
#11 ((fluid NEXT (manage* or therap* or resuscitat*))):TI,AB,KY AND SR-INJ:CC
#12 (#9 OR #10 OR #11)
#13 (#8 AND #12)
Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library)
#1 ((hypertonic or hyper-tonic) near (saline or salt or sodium chloride or NaCl))
#2 hts:ti,ab,kw
#3 MeSH descriptor: [Saline Solution, Hypertonic] this term only
#4 MeSH descriptor: [Hypertonic Solutions] this term only
#5 MeSH descriptor: [Sodium Chloride] this term only
#6 MeSH descriptor: [Fluid Therapy] this term only and with qualifier(s): [Methods - MT, Standards - ST]
#7 (fluid and (manage* or therap* or resuscitat*)):ti
#8 (osmotherap* or "osmo* therap*" or "hyperosmo* therap*" or osmolar* or hyperosmolar*)
#9 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
#10 MeSH descriptor: [Intracranial Pressure] this term only
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#11 MeSH descriptor: [Intracranial Hypertension] explode all trees
#12 MeSH descriptor: [Brain Edema] explode all trees
#13 ((head or crani* or cerebr* or brain* or intra-cran* or intracran* or intra-cereb* or intracereb*) near (haematoma* or hematoma* or
haemorrhag* or hemorrhag* or hernia* or bleed* or pressure or hypertensi* or oedema or edema or swell*))
#14 ICP:ab (Word variations have been searched)
#15 (TBI or mTBI or sTBI)
#16 MeSH descriptor: [Cerebrovascular Trauma] explode all trees
#17 MeSH descriptor: [Craniocerebral Trauma] explode all trees
#18 ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or intracran* or intra-cereb* or
intracereb*) near (infarct* or injur* or trauma* or damag* or wound* or fracture* or contusion*))
#19 MeSH descriptor: [Glasgow Coma Scale] explode all trees
#20 MeSH descriptor: [Glasgow Outcome Scale] explode all trees
#21 MeSH descriptor: [Unconsciousness] in all MeSh products
#22 ("subarachnoid h?emorrhage" or tSAH)
#23 (diLuse axonal injury or diLuse axonal injuries or persistent vegetative state or glasgow outcome scale or glasgow coma scale):ti,ab,kw
(Word variations have been searched)
#24 ((unconscious* or coma* or concuss* or postconcuss*) near (injur* or trauma* or damag* or wound* or fracture*))
#25 ((midbrain or mid brain) next syndrome)
#26 (#9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25)
#27 (#9 and # 26)
Ovid MEDLINE databases
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
1. randomi#ed.ab,ti.
2. randomized controlled trial.pt.
3. controlled clinical trial.pt.
4. placebo.ab.
5. clinical trials as topic.sh.
6. double blind method.sh.
7. randomly.ab.
8. (RCT or at random or (random* adj (assign* or allocat* or divid* or division or number))).ti,ab,kf.
9. trial.ti.
10. or/1-9
11. (animals not (humans and animals)).sh.
12. 10 not 11
13. Intracranial Pressure/
14. exp Intracranial Hypertension/
15. ((head or crani* or cerebr* or brain* or intra-cran* or intracran* or intra-cereb* or intracereb*) adj3 (haematoma* or hematoma* or
haemorrhag* or hemorrhag* or hernia* or bleed* or pressure or hypertensi* or oedema or edema or swell*)).ti,ab,kf.
16. Brain Edema/
17. exp Craniocerebral Trauma/
18. Glasgow Coma Scale/
19. Glasgow Outcome Scale/
20. exp Unconsciousness/
21. exp Cerebrovascular Trauma/
22. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or intracran* or intra-cereb* or
intracereb*) adj3 (infarct* or injur* or trauma* or damag* or wound* or fracture* or contusion*)).ab,ti,kf.
23. (Glasgow adj3 (coma or outcome) adj3 (scale* or score*)).ab,ti,kf.
24. rancho los amigos scale.ti,ab,kf.
25. diLuse axonal injur*.ti,ab,kf.
26. ((unconscious* or coma* or concuss* or postconcuss* or 'persistent vegetative state') adj3 (injur* or trauma* or damag* or wound*
or fracture*)).ti,ab,kf.
27. (subarachnoid h?emorrhage or tSAH).ti,ab,kf.
28. ((midbrain or mid brain) adj syndrome).ti,ab,kf.
29. (TBI or mTBI or sTBI).ti,ab,kf.
30. or/13-29
31. Sodium Chloride/
32. Saline Solution, Hypertonic/
33. Hypertonic Solutions/ad, st, tu, th [Administration & Dosage, Standards, Therapeutic Use, Therapy]
34. ((hypertonic or hyper-tonic) adj3 (saline or salt or sodium chloride or NaCl)).ti,ab,kf,nm.
35. HTS.ab,ti,kf.
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36. Fluid Therapy/
37. (osmotherap* or osmo* therap* or hyperosmo* therap*).ti,ab,kf.
38. (hyperosmolar* or hyper osmolar*).ti,ab,kf.
39. or/31-38
40. 12 and 30 and 39
41. remove duplicates from 40
Ovid Embase
1. randomized controlled trial/






8. ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask* or dummy)).ti,ab,kw.
9. double blind procedure/
10. (RCT or at random or (random* adj (assign* or allocat* or divid* or division or number))).ti,ab,kw.
11. trial.ti.
12. or/1-11
13. ((animal or nonhuman) not (human and (animal or nonhuman))).de.
14. 12 not 13
15. intracranial pressure/
16. exp intracranial hypertension/
17. ((head or crani* or cerebr* or brain* or intra-cran* or intracran* or intra-cereb* or intracereb*) adj3 (haematoma* or hematoma* or
haemorrhag* or hemorrhag* or hernia* or bleed* or pressure or hypertensi* or oedema or edema or swell*)).ti,ab,kw.
18. ICP.ab.




23. exp brain injury/
24. cerebrovascular accident/
25. exp brain injury assessment/
26. exp unconsciousness/
27. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or intracran* or intra-cereb* or
intracereb*) adj3 (infarct* or injur* or trauma* or damag* or wound* or fracture* or contusion*)).ab,ti,kw.
28. (Glasgow adj3 (coma or outcome) adj3 (scale* or score*)).ab,ti,kw.
29. rancho los amigos scale.ti,ab,kw.
30. diLuse axonal injur*.ti,ab,kw.
31. ((unconscious* or coma* or concuss* or postconcuss* or 'persistent vegetative state') adj3 (injur* or trauma* or damag* or wound*
or fracture*)).ti,ab,kw.
32. (subarachnoid h?emorrhage or tSAH).ti,ab,kw.
33. ((midbrain or mid brain) adj syndrome).ti,ab,kw.
34. (TBI or mTBI or sTBI).ti,ab,kw.
35. or/15-34
36. ((hypertonic or hyper-tonic) adj3 (saline or salt or sodium chloride or NaCl)).ti,ab,kw,rn.
37. sodium chloride/ and hypertonic solution/
38. ((hypertonic or fluid) adj3 (therapy or resuscitat*)).ti,kw.
39. *fluid therapy/
40. fluid resuscitation/
41. (osmotherap* or osmo* therap* or hyperosmo* therap*).ti,ab,kw.
42. or/36-41
43. 14 and 35 and 42
44. (rat or rats or mouse or mice or rodent* or pig or pigs or piglet* or swine or porcine or murine or sheep or lambs or rabbit or rabbits
or cat or cats or feline or dog or dogs or canine).ti.
45. 43 not 44
46. remove duplicates from 45
Web of Science
Science Citation Index-Expanded (SCI-EXPANDED)
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Conference Proceedings Citation Index-Science (CPCI-S)
TS=((randomised or randomized or randomly or “random order” or “random sequence” or “random allocation” or “randomly allocated”
or “at random” or placebo or ((singl* or doubl* or trebl* or tripl*) same (blind* or mask*))) AND (((hypertonic or hyper-tonic) same (saline
or salt or sodium chloride or NaCl))) AND (((head or crani* or cerebr* or brain* or intra-cran* or intracran* or intra-cereb* or intracereb*)
same (haematoma* or hematoma* or haemorrhag* or hemorrhag* or hernia* or bleed* or pressure or hypertensi* or oedema or edema
or swell*)) or ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or intracran* or intra-cereb*
or intracereb*) same (infarct* or injur* or trauma* or damag* or wound* or fracture* or contusion*)) or “diLuse axonal injur*” or “glasgow
outcome scale” or “glasgow coma scale” or TBI or sTBI or "subarachnoid h?emorrhage" or tSAH)) NOT TI=(rat or rats or mouse or mice
or rodent* or pig or pigs or piglet* or swine or porcine or murine or sheep or lambs or rabbit or rabbits or cat or cats or feline or dog or
dogs or canine)
Appendix 2. Searches to Dec 2013 (English language sources)
Cochrane Injuries Group specialised register
((fluid management or sodium or fluid therapy* or hypertonic saline resuscitation or maintenance fluid* or "hts" or hypertonic saline
infusion* or hypertonic sodium chloride solution*) AND (((haematoma* or hematoma* or haemorrhag* or hemorrhage* or bleed* or
pressure) adj3 (head or cranial or cerebral or brain* or intra-cranial or inter-cranial)) or (diLuse axonal injury or diLuse axonal injuries or
persistent vegetative state or glasgow outcome scale or Glasgow coma scale) or ((injury* or injuries or trauma or damage or damaged
or wound* or fracture*OR contusion* or haematoma* or hematoma* or Haemorrhag* or hemorrhag* or bleed* or pressure) adj3
(unconscious* or coma* or concuss*)))) AND ( INREGISTER)
Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library
#1fluid management:ti,ab,kw (Word variations have been searched)
#2sodium:ti,ab,kw (Word variations have been searched)
#3fluid therapy*:ti,ab,kw (Word variations have been searched)
#4hypertonic saline resuscitation:ti,ab,kw (Word variations have been searched)
#5maintenance fluid*:ti,ab,kw (Word variations have been searched)
#6"hts":ti,ab,kw (Word variations have been searched)
#7hypertonic saline infusion*:ti,ab,kw (Word variations have been searched)
#8hypertonic sodium chloride solution*:ti,ab,kw (Word variations have been searched)
#9MeSH descriptor: [Saline Solution, Hypertonic] explode all trees
#10MeSH descriptor: [Hypertonic Solutions] this term only
#11MeSH descriptor: [Fluid Therapy] explode all trees
#12MeSH descriptor: [Sodium] explode all trees
#13MeSH descriptor: [Sodium Chloride] explode all trees
#14#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15MeSH descriptor: [Craniocerebral Trauma] explode all trees
#16MeSH descriptor: [Brain Edema] explode all trees
#17MeSH descriptor: [Glasgow Coma Scale] explode all trees
#18MeSH descriptor: [Glasgow Outcome Scale] explode all trees
#19MeSH descriptor: [Unconsciousness] explode all trees
#20MeSH descriptor: [Cerebrovascular Trauma] explode all trees
#21((haematoma* or hematoma* or haemorrhag* or hemorrhage* or bleed* or pressure) near/3 (head or cranial or cerebral or brain* or
intra-cranial or inter-cranial)):ti,ab,kw (Word variations have been searched)
#22(diLuse axonal injury or diLuse axonal injuries or persistent vegetative state or glasgow outcome scale or glasgow coma scale):ti,ab,kw
(Word variations have been searched)
#23((injury* or injuries or trauma or damage or damaged or wound* or fracture*OR contusion* or haematoma* or hematoma* or
Haemorrhag* or hemorrhag* or bleed* or pressure) near/3 (unconscious* or coma* or concuss*)):ti,ab,kw (Word variations have been
searched)




((((((((((fluid management[Title/Abstract]) OR sodium[Title/Abstract] OR fluid therapy*[Title/Abstract]) OR hypertonic saline
resuscitation[Title/Abstract]) OR maintenance fluid*[Title/Abstract]) OR "hts"[Title/Abstract]) OR hypertonic saline infusion*[Title/
Abstract]) OR hypertonic sodium chloride solution*[Title/Abstract])) OR ((((("Saline Solution, Hypertonic"[Mesh]) OR "Hypertonic
Solutions"[Mesh:NoExp]) OR "Fluid Therapy"[Mesh]) OR "Sodium"[Mesh]) OR "Sodium Chloride"[Mesh]))) AND ((((((((("Comparative
Study"[Publication Type]) OR "Randomized Controlled Trial"[Publication Type]) OR "Controlled Clinical Trial"[Publication Type]))
OR (((((((randomized[Title/Abstract]) OR randomised[Title/Abstract]) OR placebo[Title/Abstract]) OR randomly[Title/Abstract]) OR
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trial[Title/Abstract]) OR groups[Title/Abstract]) OR group[Title/Abstract]))) NOT (("Animals"[Mesh]) NOT ("Animals"[Mesh] AND
"Humans"[Mesh])))) AND (((((((((((((("Craniocerebral Trauma"[Mesh])) OR "Brain Edema"[Mesh]) OR "Glasgow Coma Scale"[Mesh]) OR
"Glasgow Outcome Scale"[Mesh]) OR "Unconsciousness"[Mesh]) OR "Cerebrovascular Trauma"[Mesh])) OR ((((((((haematoma*[Title/
Abstract]) OR hematoma*[Title/Abstract]) OR haemorrhag*[Title/Abstract]) OR hemorrhage*[Title/Abstract]) OR bleed*[Title/Abstract])
OR pressure[Title/Abstract])) AND ((((((head[Title/Abstract]) OR cranial[Title/Abstract]) OR cerebral[Title/Abstract]) OR brain*[Title/
Abstract]) OR intra-cranial[Title/Abstract]) OR inter-cranial[Title/Abstract]))) OR (((((diLuse axonal injury[Title/Abstract]) OR diLuse axonal
injuries[Title/Abstract]) OR persistent vegetative state[Title/Abstract]) OR glasgow outcome scale[Title/Abstract]) OR glasgow coma
scale[Title/Abstract])) OR ((((((((((((((((injury*[Title/Abstract]) OR injuries[Title/Abstract]) OR trauma[Title/Abstract]) OR damage[Title/
Abstract]) OR damaged[Title/Abstract]) OR wound*[Title/Abstract]) OR fracture*[Title/Abstract]) OR contusion*[Title/Abstract]) OR
haematoma*[Title/Abstract]) OR hematoma*[Title/Abstract]) OR Haemorrhag*[Title/Abstract]) OR hemorrhag*[Title/Abstract]) OR
bleed*[Title/Abstract]) OR pressure[Title/Abstract])) AND (((unconscious*[Title/Abstract]) OR coma*[Title/Abstract]) OR concuss*[Title/
Abstract]))))))




4. hypertonic saline resuscitation.tw.
5. maintenance fluid*.tw.
6. "hts".tw.
7. hypertonic saline infusion*.tw.
8. hypertonic sodium chloride solution*.tw.
9. sodium chloride/
10. hypertonic solution/
11. exp fluid therapy/
12. sodium/
13. or/1-12
14. exp head injury/
15. brain edema/
16. Glasgow coma scale/
17. Glasgow outcome scale/
18. exp unconsciousness/
19. exp cerebrovascular accident/
20. ((haematoma* or hematoma* or haemorrhag* or hemorrhage* or bleed* or pressure) adj3 (head or cranial or cerebral or brain* or
intra-cranial or inter-cranial)).ab,ti.
21. (diLuse axonal injury or diLuse axonal injuries or persistent vegetative state or glasgow outcome scale or glasgow coma scale).ab,ti.
22. ((injury* or injuries or trauma or damage or damaged or wound* or fracture*OR contusion* or haematoma* or hematoma* or
Haemorrhag* or hemorrhag* or bleed* or pressure) adj3 (unconscious* or coma* or concuss*)).ab,ti.
23. or/14-22
24. 13 and 23
25. exp Randomized Controlled Trial/
26. exp controlled clinical trial/





32. exp major clinical study/
33. randomly.ab.
34. (trial or study).ti.
35. 25 or 26 or 27 or 29 or 30 or 31 or 32 or 33 or 34
36. exp animal/ not (exp human/ and exp animal/)
37. 35 not 36
38. 24 and 37
ISI Web of Science: Science Citation Index-Expanded (SCI-EXPANDED) & Conference Proceedings Citation Index-Science (CPCI-S)
#18#17 AND #9 AND #6
#17#16 OR #13 OR #12
#16#15 AND #14
#15TS=(unconscious* or coma* or consuss*)
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#14TS=(injur* or trauma or damag* or wound* or fracture* or contusion* or haematoma* or hematoma* or haemorrhag* or hemorrhag*
or bleed* or pressure)
#13TS=("diLuse axonal injur*" or "persistent vegetative state" or "glasgow outcome scale" or "glasgow coma scale")
#12#11 AND #10
#11TS=(head or cranial or cerebral or brain* or intra-cranial or inter-cranial)
#10TS=(haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure)
#9#8 OR #7
#8TS=("hypertonic sodium chloride solution*")




#4#3 OR #2 OR #1
#3TS=((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*))
#2TS=(controlled clinical trial OR controlled trial OR clinical trial OR placebo)
#1TS=(randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly allocated
OR at random OR randomized controlled trial)




















#20 CT=动物 AND NOT（CT=⼈类 AND CT=动物）
#21 #1-#11/ OR 查找包括随机试验在内的所有临床实验⽂献）
#22 #21 AND NOT #20（排除动物试验后所有⼈体实验的临床实验⽂献）
#23 #12-#19/OR（查找所有包括评价、对⽐、随访及前瞻性研究的⽂献）
#24 #23 AND NOT #20（排除动物试验后所有包括评价、对⽐、随访及前瞻性研究的⽂献）
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#60 "⾎肿"[常⽤字段:智能]
#61 "⽔肿"[常⽤字段:智能]
#62 #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61
#63 "昏迷"[常⽤字段:智能]
#64 "震荡"[常⽤字段:智能]
#65 #63 OR #64
#66 #62 AND #65
#67 #43 OR #48 OR #54 OR #66
#68 #25 AND #36 AND #67
W H A T ' S   N E W
 
Date Event Description
16 January 2020 New citation required but conclusions
have not changed
This review was republished to enable electronic databases to
hold a copy of the final version. This review was first published
on 30 December 2019 but was not electronically linked to some
online databases. No changes have been made to the text of the
review; republication was solely in order to overcome a techno-
logical problem.
 
H I S T O R Y
Protocol first published: Issue 2, 2014
Review first published: Issue 12, 2019
 
Date Event Description
30 December 2019 Amended Minor copy edits made to the table of excluded studies.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
• In the protocol for this review (Chen 2014), we intended to include people with acute traumatic brain injury only; however, eligible
trials are so few that we were obliged to include trials with mixed populations within the final review. Two trials included people who
did not have a traumatic brain injury but did have increased intracranial pressure (Francony 2008; Harutjunyan 2005). Naturally this
complicates interpretation of the results; however, we did not perform any meta-analysis including data from these trials and comment
on the heterogeneity of participants where relevant.
• In the Types of interventions section, we included any hypertonic saline in any dosage for any duration in the protocol, but in the
review we excluded a trial that compared sodium lactate with mannitol in the treatment of intracranial hypertensive episodes in
severe traumatic brain injury. Sodium lactate is a hyperosmolar solution but it diLers fundamentally from sodium chloride because
lactate is a metabolisable anion which means that even with comparable osmolarity in the bottle, sodium lactate becomes two times
less hypertonic than equiosmotic sodium chloride. The eLect of sodium lactate could not be attributed to a 'classical osmotic eLect'
as sodium lactate administration was not associated with any increase in plasma osmolality, contrary to the equiosmotic mannitol
administration which was associated with a concomitant increase in plasma osmolality (personal communication Ichai 2009).
• Under 'Methods', we had not planned to consider conducting 'best-worst case' scenarios, but missing mortality data in a key trial made
this seem a reasonable course in order to demonstrate the parameters of uncertainty for important outcomes including mortality and
'poor outcome' on the Glasgow Outcome Scale (GOS).
• We have included plans for future updates to incorporate continuous data, if necessary, given the variation with which intracranial
pressure values are reported.
• In future updates, we may, if appropriate, use Trial Sequential Analysis (CIG 2015).
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